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ABSTRACT	  	  	  Selected	  Neuropharmacology	  of	  Resurgence	  	  	  by	  	  	  Adam	  D.	  Pyszczynski,	  Doctor	  of	  Philosophy	  	  Utah	  State	  University,	  2013	  	  	  Major	  Professor:	  Timothy	  A.	  Shahan	  Department:	  Psychology	  	  	   Resurgence	  refers	  to	  the	  reappearance	  of	  an	  extinguished	  operant	  behavior	  when	  reinforcement	  for	  an	  alternative	  behavior	  is	  also	  discontinued.	  It	  is	  especially	  relevant	  to	  the	  reappearance	  of	  problem	  behavior	  because	  many	  behavioral	  interventions	  discontinue	  reinforcement	  for	  aberrant	  behavior	  while	  simultaneously	  reinforcing	  an	  appropriate	  response.	  Existing	  information	  about	  the	  neuropharmacology	  of	  resurgence	  is	  scarce,	  but	  suggests	  overlap	  between	  drug	  seeking	  observed	  in	  the	  resurgence	  model	  and	  drug	  seeking	  observed	  in	  the	  more	  widely	  studied	  reinstatement	  and	  renewal	  models.	  The	  aim	  of	  this	  dissertation	  was	  to	  explore	  additional	  neural	  systems	  relevant	  to	  reinstatement	  and	  renewal	  preparations	  within	  a	  resurgence	  paradigm	  to	  assess	  further	  overlap.	  The	  neuropharmacology	  of	  resurgence	  was	  examined	  in	  two	  studies	  via	  administration	  of	  two	  drugs	  that	  have	  proven	  effective	  in	  blocking	  drug	  seeking	  in	  reinstatement	  and	  renewal	  preparations.	  In	  two	  experiments,	  rats	  earned	  food	  pellets	  for	  pressing	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a	  target	  lever	  in	  Phase	  I.	  In	  Phase	  II,	  lever	  pressing	  no	  longer	  produced	  food,	  but	  food	  was	  delivered	  contingent	  on	  an	  alterative	  nose	  poke	  response.	  Finally	  in	  Phase	  III,	  neither	  response	  produced	  food	  deliveries.	  Prior	  to	  these	  Phase	  III	  sessions,	  separate	  groups	  of	  rats	  were	  injected	  with	  0,	  50,	  or	  100	  µg/kg	  of	  the	  dopamine	  D2	  receptor	  antagonist	  raclopride	  in	  Experiment	  1	  or	  0,	  20,	  or	  40	  µg/kg	  of	  α2	  agonist	  clonidine	  in	  Experiment	  2.	  Both	  doses	  of	  raclopride	  were	  effective	  in	  blocking	  resurgence,	  but	  there	  was	  strong	  evidence	  that	  the	  higher	  dose	  did	  so	  via	  motor	  rather	  than	  motivational	  impairment.	  Furthermore,	  the	  lower	  dose	  significantly	  suppressed	  the	  alternative	  nose	  poke,	  which	  suggests	  motor	  impairment,	  as	  well.	  Only	  the	  higher	  dose	  of	  clonidine	  blocked	  resurgence,	  but	  did	  so	  with	  no	  evidence	  of	  motor	  impairment.	  Raclopride	  significantly	  impacted	  extinction	  of	  the	  alternative	  poke	  at	  both	  doses	  tested,	  whereas	  clonidine	  had	  no	  effect	  at	  either	  dose.	  The	  results	  of	  the	  present	  studies	  provide	  additional	  information	  about	  the	  neuropharmacology	  of	  resurgence,	  as	  well	  as	  additional	  evidence	  of	  overlap	  between	  resurgence,	  reinstatement,	  and	  renewal.	  The	  present	  results	  may	  also	  have	  implications	  regarding	  underlying	  neural	  mechanisms	  and	  for	  pharmacotherapies	  to	  attenuate	  relapse	  when	  alternative	  sources	  of	  reinforcement	  are	  thinned	  or	  discontinued.	   (125	  pages)	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PUBLIC	  ABSTRACT	  	  	  Selected	  Neuropharmacology	  of	  Resurgence	  	  	  by	  	  	  Adam	  D.	  Pyszczynski,	  Doctor	  of	  Philosophy	  	  Utah	  State	  University,	  2013	  	  The	  reemergence	  of	  problem	  behavior	  (i.e.,	  relapse)	  is	  a	  key	  concern	  in	  most	  behavioral	  interventions.	  Resurgence	  refers	  to	  the	  reappearance	  of	  a	  previously	  rewarded	  behavior	  when	  reward	  for	  an	  alternative	  behavior	  is	  also	  discontinued.	  It	  is	  especially	  relevant	  to	  the	  reappearance	  of	  problem	  behavior	  because	  many	  behavioral	  interventions	  discontinue	  reward	  for	  aberrant	  behavior	  while	  simultaneously	  rewarding	  an	  appropriate	  response.	  	  Understanding	  the	  underlying	  neuropharmacology	  of	  behavioral	  phenomena	  such	  as	  resurgence	  is	  important	  because	  it	  helps	  elucidate	  the	  neural	  processes	  at	  the	  root	  of	  such	  behavior,	  and	  also	  has	  implications	  for	  pharmacotherapies.	  Existing	  information	  about	  the	  neuropharmacology	  of	  resurgence	  is	  scarce,	  but	  suggests	  overlap	  between	  relapse	  observed	  in	  the	  resurgence	  model	  and	  relapse	  observed	  in	  the	  more	  widely	  studied	  reinstatement	  and	  renewal	  models.	  The	  aim	  of	  this	  dissertation	  was	  to	  explore	  additional	  neural	  systems	  relevant	  to	  reinstatement	  and	  renewal	  preparations	  within	  a	  resurgence	  paradigm	  to	  assess	  further	  overlap.	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The	  neuropharmacology	  of	  resurgence	  was	  examined	  in	  two	  studies	  via	  administration	  of	  two	  drugs	  that	  have	  proven	  effective	  in	  blocking	  the	  reemergence	  of	  behavior	  in	  reinstatement	  and	  renewal	  preparations.	  In	  two	  experiments,	  rats	  were	  rewarded	  with	  food	  for	  pressing	  a	  target	  lever	  in	  Phase	  I.	  The	  lever	  no	  longer	  produced	  food	  in	  Phase	  II,	  but	  was	  delivered	  contingent	  on	  an	  alterative	  nose	  poke	  response.	  Finally	  in	  Phase	  III,	  neither	  response	  produced	  food	  deliveries.	  Prior	  to	  Phase	  III	  sessions,	  separate	  groups	  of	  rats	  were	  injected	  with	  various	  doses	  of	  the	  dopamine	  D2	  receptor	  antagonist	  raclopride	  in	  Experiment	  1,	  or	  the	  α2	  agonist	  clonidine	  in	  Experiment	  2.	  	  Both	  raclopride	  and	  clonidine	  dose-­‐dependently	  attenuated	  the	  reemergence	  of	  the	  target	  lever	  press.	  However,	  there	  was	  evidence	  that	  raclopride	  may	  have	  impacted	  motor	  behavior	  at	  both	  doses,	  whereas	  rats	  treated	  with	  clonidine	  showed	  no	  such	  deficits.	  Raclopride	  also	  significantly	  impacted	  rate	  of	  decline	  of	  the	  alternative	  poke	  at	  both	  doses	  tested,	  whereas	  clonidine	  had	  no	  effect	  at	  either	  dose.	  	  The	  results	  of	  the	  present	  studies	  provide	  additional	  information	  about	  the	  neuropharmacology	  of	  resurgence,	  as	  well	  as	  additional	  evidence	  of	  overlap	  between	  resurgence,	  reinstatement,	  and	  renewal.	  These	  results	  have	  implications	  regarding	  underlying	  neural	  mechanisms	  and	  pharmacotherapies	  to	  attenuate	  relapse	  when	  alternative	  sources	  of	  reinforcement	  are	  thinned	  or	  discontinued.	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CHAPTER	  I	  INTRODUCTION	  
Resurgence	  is	  a	  behavioral	  phenomenon	  in	  which	  extinguished	  operant	  behavior	  reappears	  at	  the	  onset	  of	  extinction	  of	  an	  alternative	  response	  (Epstein,	  1983).	  Differential	  reinforcement	  of	  alternative	  (DRA)	  behavior	  procedures,	  in	  which	  the	  reinforcing	  consequences	  of	  problem	  behavior	  are	  withheld	  while	  appropriate	  behaviors	  are	  reinforced,	  are	  a	  widely	  used	  and	  effective	  method	  of	  treatment	  (see	  Petscher,	  Rey,	  &	  Bailey,	  2009).	  However,	  reduction	  or	  elimination	  of	  reinforcement	  for	  the	  alternative	  response	  tends	  to	  result	  in	  increased	  levels	  of	  the	  problem	  behavior	  (Volkert,	  Lerman,	  Call,	  &	  Trosclair-­‐Lasserre,	  2009).	  Thus,	  resurgence	  has	  applied	  importance	  because	  it	  describes	  relapse	  common	  to	  DRA-­‐based	  behavioral	  interventions.	  	  Reinstatement	  (Campbell,	  Phillips,	  Fixsen,	  &	  Crumbaugh,	  1968;	  Rescorla	  &	  Skucy,	  1969)	  and	  renewal	  (Bouton	  &	  Bolles,	  1979)	  are	  two	  other	  behavioral	  phenomena	  that	  produce	  the	  reappearance	  of	  previously	  reinforced	  responding.	  Regarding	  relapse	  to	  problem	  behavior,	  both	  procedures	  have	  been	  widely	  used	  to	  model	  relapse	  to	  drug	  seeking	  in	  animal	  subjects.	  Reinstatement	  refers	  to	  extinguished	  responding	  that	  reoccurs	  despite	  continued	  absence	  of	  drug	  upon	  re-­‐exposure	  to	  the	  previously	  self-­‐administered	  drug,	  drug-­‐associated	  cues,	  or	  stress	  (see	  Shaham,	  Shalev,	  Lu,	  de	  Wit,	  &	  Stewart,	  2003).	  Renewal	  refers	  to	  drug	  seeking	  that	  occurs	  when	  contextual	  changes	  accompany	  changes	  in	  drug	  availability:	  Drug-­‐
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maintained	  responding	  is	  trained	  in	  one	  distinct	  context,	  extinguished	  in	  a	  different	  context,	  and	  then	  increases	  when	  the	  subject	  is	  reintroduced	  to	  the	  original	  self-­‐administration	  context	  (see	  Crombag,	  Bossert,	  Koya,	  &	  Shaham,	  2008).	  Although	  resurgence	  may	  pose	  a	  significant	  risk	  for	  relapse	  within	  applied	  settings	  in	  which	  alternative	  reinforcement	  is	  used,	  little	  is	  known	  about	  the	  underlying	  neuropharmacology	  of	  resurgence.	  Quick,	  Pyszczynski,	  Colston,	  and	  Shahan	  (2011)	  found	  that	  administration	  of	  the	  dopamine	  D1	  receptor	  antagonist	  SCH	  23390	  blocked	  resurgence	  of	  cocaine	  seeking.	  Dopamine	  D1	  receptor	  activation	  also	  plays	  a	  critical	  role	  in	  various	  types	  of	  reinstatement	  and	  renewal	  of	  drug	  seeking	  (e.g.,	  Alleweireldt,	  Weber,	  Kirschner,	  Bullock,	  &	  Neisewander,	  2002;	  Capriles,	  Rodaros,	  Sorge,	  &	  Stewart,	  2003;	  Crombag,	  Grimm,	  &	  Shaham,	  2002;	  Norman,	  Norman,	  Hall,	  &	  Tsibulsky,	  1999),	  so	  the	  Quick	  et	  al.	  results	  indicate	  common	  neuropharmacology	  among	  the	  models	  of	  relapse	  to	  drug	  seeking.	  	  Considerably	  more	  is	  known	  about	  the	  neuropharmacology	  of	  reinstatement	  and	  renewal	  (see	  Crombag	  et	  al.,	  2008;	  Bossert,	  Ghitza,	  Lu,	  Epstein,	  &	  Shaham,	  2005;	  Shalev,	  Grimm,	  &	  Shaham,	  2002).	  If	  resurgence	  shares	  common	  neurobiology	  with	  these	  models,	  as	  the	  Quick	  et	  al.	  (2011)	  data	  suggest,	  then	  other	  neural	  systems	  critical	  in	  reinstatement	  and	  renewal	  may	  also	  be	  critical	  to	  resurgence.	  The	  purpose	  of	  the	  present	  dissertation	  is	  to	  investigate	  the	  role	  of	  some	  of	  these	  neural	  systems	  that	  have	  been	  shown	  to	  play	  a	  substantial	  role	  in	  the	  drug	  seeking	  observed	  in	  various	  types	  of	  reinstatement	  and	  renewal	  models.	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The	  dopamine	  D2	  receptor	  is	  linked	  to	  drug-­‐induced	  reinstatement	  (e.g.,	  Shaham	  &	  Stewart,	  1996),	  cue-­‐induced	  reinstatement	  (e.g.,	  Liu	  &	  Weiss,	  2002b;	  Tobin,	  Newman,	  Quinn,	  &	  Shalev,	  2009),	  and	  renewal	  (Crombag	  et	  al.,	  2002).	  Because	  the	  D2	  receptor	  has	  not	  yet	  been	  studied	  in	  resurgence,	  and	  because	  of	  its	  importance	  in	  reinstatement	  and	  renewal,	  it	  was	  studied	  in	  Experiment	  1.	  Resurgence	  has	  been	  likened	  to	  stress-­‐induced	  relapse	  (Quick	  et	  al.,	  2011),	  but	  the	  dopamine	  D2	  receptor	  does	  not	  appear	  to	  play	  a	  role	  in	  stress-­‐induced	  reinstatement	  (Capriles	  et	  al.,	  2003;	  Shaham	  &	  Stewart,	  1996;	  Tobin	  et	  al.,	  2009).	  The	  adrenergic	  α2	  receptor,	  however,	  has	  been	  heavily	  implicated	  in	  stress-­‐induced	  reinstatement	  (Erb	  et	  al.,	  2000;	  Lê,	  Harding,	  Juzytsch,	  Funk,	  &	  Shaham,	  2005;	  Shaham,	  Highfield,	  Delfs,	  Leung,	  &	  Stewart,	  2000;	  Zislis,	  Desai,	  Prado,	  Shah,	  &	  Bruijnzeel,	  2007),	  but	  has	  not	  yet	  been	  examined	  in	  resurgence,	  so	  it	  was	  the	  target	  of	  Experiment	  2.	  The	  role	  of	  D2	  and	  α2	  receptors	  in	  resurgence	  was	  examined	  via	  administration	  of	  the	  dopamine	  D2	  antagonist	  raclopride	  and	  the	  adrenergic	  α2	  receptor	  agonist	  clonidine.	  Separate	  groups	  of	  rats	  pressed	  a	  target	  lever	  for	  food	  deliveries	  during	  Phase	  I.	  In	  Phase	  II,	  the	  lever	  press	  was	  extinguished	  while	  an	  alternative	  nose	  poke	  response	  was	  reinforced	  with	  food	  deliveries.	  Finally	  in	  Phase	  III,	  the	  alternative	  poke	  response	  was	  also	  placed	  on	  extinction	  while	  the	  target	  lever	  press	  remained	  on	  extinction.	  Prior	  to	  Phase	  III	  sessions	  the	  groups	  of	  rats	  received	  injections	  of	  50	  or	  100	  µg/kg	  of	  raclopride,	  20	  or	  40	  µg/kg	  of	  clonidine,	  or	  saline.	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Raclopride	  and	  clonidine	  dose-­‐dependently	  attenuated	  resurgence	  of	  target	  lever	  pressing	  during	  Phase	  III.	  Both	  doses	  of	  raclopride,	  but	  only	  the	  higher	  dose	  of	  clonidine	  reduced	  resurgence	  to	  levels	  statistically	  indistinguishable	  from	  the	  end	  of	  Phase	  II.	  A	  variety	  of	  measures	  were	  examined	  to	  rule	  out	  the	  possibility	  that	  the	  drugs	  reduced	  resurgence	  via	  motor	  impairment.	  There	  was	  evidence	  that	  both	  doses	  of	  raclopride	  may	  have	  impaired	  motor	  function,	  whereas	  there	  was	  no	  evidence	  of	  motor	  impairment	  within	  the	  animals	  treated	  with	  clonidine.	  The	  present	  study	  showed	  that	  D2	  and	  α2	  receptors	  are	  critical	  to	  resurgence,	  providing	  further	  evidence	  of	  common	  neurobiology	  among	  commonly	  used	  models	  of	  drug	  seeking.	  These	  results	  provide	  additional	  information	  about	  the	  neural	  mechanisms	  mediating	  resurgence,	  and	  also	  have	  implications	  for	  the	  development	  of	  pharmacotherapies	  that	  may	  be	  used	  in	  conjunction	  with	  behavioral	  interventions	  to	  reduce	  the	  likelihood	  of	  relapse.	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CHAPTER	  II	  REVIEW	  OF	  LITERATURE	  
Reduction	  of	  Problem	  Behavior	  
Reduction	  of	  problem	  behavior	  is	  the	  primary	  aim	  of	  many	  behavioral	  interventions.	  Extinction,	  which	  refers	  to	  the	  withdrawal	  of	  contingent	  reinforcement	  for	  behavior,	  is	  a	  widely	  used	  behavioral	  intervention	  (see	  Lerman	  &	  Iwata,	  1996).	  Although	  effective	  in	  reducing	  targeted	  behaviors,	  extinction	  is	  seldom	  used	  in	  isolation.	  An	  additional	  treatment	  component	  in	  which	  an	  alternative,	  appropriate	  response	  is	  reinforced	  in	  conjunction	  with	  extinction	  of	  the	  problematic	  behavior	  is	  typically	  used.	  Reinforcement	  of	  alternative	  behaviors	  in	  this	  manner	  is	  outlined	  as	  a	  necessary	  practice	  in	  the	  Guidelines	  for	  Responsible	  Conduct	  for	  Behavior	  Analysts,	  developed	  by	  the	  Behavior	  Analyst	  Certification	  Board	  (BACB)	  who	  is	  responsible	  for	  certifying	  behavior	  analysts	  (BACB,	  2010).	  	  Extinction	  used	  in	  isolation	  can	  also	  produce	  undesirable	  side	  effects.	  For	  instance,	  an	  extinction	  burst	  may	  occur,	  which	  is	  a	  temporary	  increase	  in	  the	  frequency,	  duration,	  or	  intensity	  of	  a	  response	  that	  has	  been	  placed	  on	  extinction	  (Cooper,	  Heron,	  &	  Heward,	  2007).	  Such	  increases	  may	  be	  undesirable	  when	  dealing	  with	  especially	  severe	  problem	  behavior.	  Extinction	  bursts	  are	  observed	  less	  frequently	  when	  extinction	  is	  employed	  in	  concurrence	  with	  reinforcement	  for	  alternative	  behaviors	  than	  when	  used	  in	  isolation	  (see	  Lerman	  &	  Iwata,	  1995).	  In	  addition	  to	  quickly	  reducing	  problem	  behavior	  with	  minimal	  side	  effects,	  these	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treatments	  are	  effective	  in	  addressing	  a	  number	  of	  problem	  behaviors	  and	  have	  the	  added	  benefit	  of	  training	  appropriate	  alternate	  behaviors	  (see	  Petscher	  et	  al.,	  2009).	  Procedures	  that	  provide	  reinforcement	  for	  an	  alternative	  response	  in	  conjunction	  with	  extinction	  of	  another	  behavior	  are	  broadly	  referred	  to	  as	  DRA	  behavior	  procedures	  (Cooper	  et	  al.,	  2007).	  	  An	  example	  of	  a	  DRA-­‐based	  treatment	  used	  to	  eliminate	  problem	  behavior	  is	  functional	  communication	  training	  (FCT;	  Carr	  &	  Durand,	  1985).	  Within	  FCT,	  clinicians	  first	  identify	  the	  reinforcer	  maintaining	  problem	  behavior.	  The	  reinforcer	  maintaining	  problem	  behavior	  is	  then	  withheld	  (i.e.,	  extinction)	  and	  an	  alternative	  communicative	  response	  is	  trained	  and	  maintained	  by	  contingent	  delivery	  of	  that	  same	  reinforcer,	  or	  by	  a	  reinforcer	  in	  the	  same	  class.	  When	  implemented	  properly,	  FCT	  is	  effective	  in	  addressing	  a	  variety	  of	  problem	  behaviors	  (Tiger,	  Hanley,	  &	  Bruzek,	  2008).	  A	  second	  form	  of	  DRA	  treatment	  primarily	  used	  to	  curb	  drug	  abuse	  is	  called	  Contingency	  Management	  (Bigelow,	  Stitzer,	  Griffiths,	  &	  Liebson,	  1981).	  The	  treatment	  provides	  nondrug	  incentives	  contingent	  on	  abstaining	  from	  drug	  use,	  confirmed	  via	  drug	  testing.	  A	  variety	  of	  nondrug	  incentives,	  such	  as	  vouchers	  with	  monetary	  value	  (Silverman,	  Chutuape,	  Bigelow,	  &	  Stitzer,	  1999)	  or	  access	  to	  work	  opportunities	  (Silverman,	  Svikis,	  Robles,	  Stitzer,	  &	  Bigelow,	  2001),	  are	  effective	  reinforcers	  of	  abstinence	  within	  the	  treatment.	  When	  the	  appropriate	  drug	  tests	  are	  used	  at	  regular	  intervals,	  Contingency	  Management	  is	  effective	  in	  decreasing	  drug	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use	  and	  preventing	  relapse	  to	  a	  number	  of	  different	  drugs	  of	  abuse	  (see	  Prendergast,	  Podus,	  Finney,	  Greenwell,	  &	  Roll,	  2006)	  Despite	  the	  beneficial	  outcomes	  associated	  with	  DRA	  treatments,	  the	  risk	  of	  relapse	  for	  problem	  behavior	  is	  high	  if	  alternative	  reinforcement	  for	  the	  adaptive	  behavior	  is	  discontinued	  or	  reduced	  (Volkert	  et	  al.,	  2009).	  Increases	  in	  problem	  behavior	  inflate	  the	  likelihood	  that	  problem	  behavior	  will	  contact	  reinforcement	  and	  will	  be	  maintained,	  posing	  a	  serious	  threat	  to	  treatment	  efficacy	  and	  durability.	  	  Thus,	  this	  type	  of	  relapse	  is	  a	  primary	  concern	  in	  treatments	  employing	  DRA	  methods.	  
Resurgence	  
Resurgence	  refers	  to	  the	  reappearance	  of	  an	  extinguished	  response	  when	  reinforcement	  for	  an	  alternative	  response	  is	  also	  discontinued	  (Epstein,	  1983).	  In	  laboratory	  experiments	  on	  resurgence,	  the	  procedure	  generally	  consists	  of	  three	  phases.	  First,	  a	  response	  (Response	  1)	  is	  trained	  and	  maintained	  via	  contingent	  reinforcement.	  Next,	  Response	  1	  is	  placed	  on	  extinction,	  resulting	  in	  decreased	  levels	  of	  that	  response,	  while	  an	  alternative	  response	  (Response	  2)	  is	  introduced	  and	  reinforced.	  Finally,	  Response	  2	  is	  also	  extinguished,	  and	  despite	  continued	  extinction,	  Response	  1	  increases	  in	  frequency	  at	  the	  onset	  of	  extinction	  of	  the	  alternative	  response.	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Because	  resurgence	  refers	  to	  reappearance	  of	  past	  behaviors	  when	  reinforcement	  for	  alternative	  behaviors	  is	  withheld,	  it	  is	  especially	  relevant	  to	  relapse	  observed	  under	  DRA-­‐based	  treatments.	  In	  applied	  settings,	  the	  problematic	  behavior	  is	  analogous	  to	  Response	  1	  while	  the	  adaptive	  behavior	  is	  like	  Response	  2.	  As	  a	  behavioral	  intervention,	  reinforcement	  is	  discontinued	  for	  the	  problem	  behavior	  while	  delivered	  contingent	  on	  an	  appropriate	  response.	  If	  for	  any	  reason	  reinforcement	  of	  the	  appropriate	  response	  ceases,	  problem	  behavior	  tends	  to	  reoccur.	  The	  role	  of	  resurgence	  in	  relapse	  of	  behaviors	  treated	  via	  DRA	  interventions	  has	  been	  suggested	  by	  a	  number	  of	  authors	  (Doughty	  &	  Oken,	  2008;	  Lattal	  &	  St.	  Peter	  Pipkin,	  2008;	  Shahan	  &	  Sweeney,	  2011).	  	  Volkert	  and	  colleagues	  (2009)	  specifically	  examined	  resurgence	  within	  an	  FCT	  treatment	  used	  to	  address	  problem	  behavior	  in	  children	  with	  autism	  or	  developmental	  disabilities.	  Experimenters	  first	  determined	  the	  reinforcer	  maintaining	  problem	  behavior	  of	  each	  child	  participating	  in	  the	  study.	  Then,	  in	  conjunction	  with	  discontinuation	  of	  reinforcement	  maintaining	  problem	  behavior,	  the	  children	  were	  then	  taught	  to	  request	  that	  reinforcer	  via	  an	  alternative	  communicative	  response,	  and	  this	  communicative	  response	  was	  reinforced	  for	  a	  number	  of	  sessions.	  Finally,	  neither	  problem	  behavior	  nor	  the	  new	  adaptive	  response	  was	  reinforced.	  Volkert	  and	  colleagues	  tested	  the	  effects	  of	  discontinuing	  (Experiment	  1)	  and	  reducing	  reinforcement	  (Experiment	  2)	  for	  the	  alternative	  communicative	  response,	  and	  found	  that	  problem	  behavior	  increased	  above	  levels	  observed	  during	  FCT	  in	  both	  cases.	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In	  a	  similar	  preparation,	  Wacker	  et	  al.	  (2011)	  examined	  the	  durability	  of	  an	  FCT	  treatment	  for	  children	  displaying	  destructive	  behavior.	  FCT	  was	  used	  to	  decrease	  the	  destructive	  behavior	  within	  the	  study,	  and	  periodic	  extinction	  probes	  were	  conducted	  to	  determine	  whether	  destructive	  behavior	  reemerged	  under	  circumstances	  in	  which	  neither	  the	  destructive	  nor	  alternative	  responses	  were	  reinforced.	  Wacker	  and	  colleagues	  reported	  increases	  in	  destructive	  behavior	  during	  early	  extinction	  probes,	  but	  the	  increases	  were	  attenuated	  as	  the	  children	  were	  exposed	  to	  more	  of	  the	  FCT	  treatment.	  These	  increases	  in	  problem	  behavior	  during	  extinction	  probes,	  and	  subsequent	  decreases	  in	  magnitude	  of	  those	  increases	  with	  longer	  exposure	  to	  treatment,	  were	  well	  described	  by	  a	  quantitative	  model	  of	  resurgence	  proposed	  by	  Shahan	  and	  Sweeney	  (2011).	  
Relapse	  to	  Drug	  Seeking	  
As	  noted	  earlier,	  Contingency	  Management	  is	  a	  DRA-­‐based	  intervention	  for	  drug	  abuse	  in	  which	  individuals	  submit	  to	  regular	  drug	  testing	  and	  are	  provided	  with	  nondrug	  incentives	  contingent	  on	  negative	  drug	  tests	  (Bigelow	  et	  al.,	  1981).	  Resurgence-­‐like	  mechanisms	  may	  also	  be	  relevant	  to	  relapse	  to	  drug	  taking	  within	  Contingency	  Management	  treatments	  in	  that	  drug	  use	  tends	  to	  increase	  once	  the	  treatment	  ends	  and	  nondrug	  alternatives	  are	  no	  longer	  provided.	  For	  instance,	  Silverman	  et	  al.	  (1999)	  reported	  dramatic	  relapse	  to	  cocaine	  taking	  once	  the	  treatment	  was	  discontinued.	  Furthermore,	  a	  meta-­‐analysis	  on	  Contingency	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Management	  reported	  a	  downward	  trend	  in	  effect	  size	  as	  time	  increased	  after	  treatment	  cessation	  (Prendergrast	  et	  al.,	  2006).	  	  There	  is	  also	  evidence	  that	  other	  events	  that	  can	  be	  interpreted	  as	  instances	  of	  alternative	  reinforcement	  loss	  can	  cause	  relapse.	  For	  instance,	  job	  loss	  and	  divorce	  are	  associated	  with	  increased	  likelihood	  of	  relapse	  (Falba,	  Teng,	  Sindelar,	  &	  Gallo,	  2005;	  Gallo,	  Bradley,	  Siegel,	  &	  Kasl,	  2001;	  San	  Jose,	  Van	  Oers,	  Van	  De	  Mheen,	  Garretsen,	  &	  Mackenbach,	  2000;	  Temple,	  Fillmore,	  Hartka,	  Johnstone,	  Leino,	  &	  Motoyoshi,	  1991).	  Based	  on	  findings	  such	  as	  these,	  the	  resurgence	  procedure	  has	  been	  applied	  as	  a	  model	  of	  relapse	  to	  drug	  seeking	  to	  determine	  whether	  loss	  of	  nondrug	  reinforcement	  produces	  relapse	  of	  extinguished	  drug	  seeking	  (Podlesnik,	  Jimenez-­‐Gomez,	  &	  Shahan,	  2006;	  Quick	  et	  al.,	  2011).	  Podlesnik	  and	  colleagues	  (2006)	  provided	  the	  first	  demonstration	  of	  resurgence	  as	  an	  animal	  model	  of	  drug	  relapse.	  In	  the	  study,	  rats	  first	  pressed	  a	  lever	  for	  alcohol	  deliveries	  during	  baseline	  sessions.	  Next,	  alcohol	  deliveries	  were	  discontinued	  resulting	  in	  decreased	  lever	  pressing.	  Concurrent	  with	  introduction	  of	  the	  extinction	  contingencies	  on	  the	  lever,	  a	  chain	  pull	  response	  was	  made	  available	  that	  produced	  food	  pellet	  deliveries.	  When	  the	  chain	  pull	  was	  also	  extinguished,	  lever	  pressing	  increased	  despite	  the	  continued	  absence	  of	  alcohol	  deliveries.	  Thus,	  Podlesnik	  et	  al.	  showed	  that	  loss	  of	  alternative	  nondrug	  reinforcement	  is	  capable	  of	  producing	  relapse	  of	  extinguished	  drug	  seeking.	  Quick	  and	  colleagues	  (2011)	  extended	  the	  resurgence	  procedure	  to	  model	  relapse	  of	  extinguished	  cocaine	  seeking.	  This	  study	  not	  only	  extended	  resurgence	  to	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another	  drug	  of	  abuse,	  but	  also	  ruled	  out	  an	  alternative	  interpretation	  of	  the	  Podlesnik	  et	  al.	  (2006)	  data	  that	  rats	  may	  have	  been	  seeking	  alcohol	  for	  its	  caloric	  value:	  Resurgence	  of	  cocaine	  seeking	  could	  not	  be	  interpreted	  as	  calorie	  seeking	  because	  cocaine	  has	  no	  caloric	  value.	  In	  the	  Quick	  et	  al.	  study,	  one	  group	  of	  rats	  initially	  lever-­‐pressed	  for	  cocaine	  deliveries,	  followed	  by	  extinction	  of	  lever	  pressing	  and	  food	  delivered	  contingent	  on	  an	  alternative	  nose	  poke	  response.	  Quick	  and	  colleagues	  found	  that	  cocaine	  seeking	  did	  in	  fact	  resurge	  when	  food	  pellets,	  introduced	  in	  parallel	  to	  discontinuation	  of	  cocaine,	  were	  also	  withheld.	  Therefore,	  discontinuation	  of	  nondrug	  reinforcement	  is	  capable	  of	  producing	  relapse	  to	  drug	  seeking,	  and	  resurgence	  appears	  to	  be	  a	  viable	  model	  of	  drug	  relapse.	  
Other	  Models	  of	  Relapse	  
Reinstatement	  (Campbell	  et	  al.,	  1968;	  Rescorla	  &	  Skucy,	  1969)	  and	  renewal	  (Bouton	  &	  Bolles,	  1979)	  are	  two	  other	  procedures	  that	  produce	  the	  reappearance	  of	  extinguished	  operant	  behavior	  (i.e.,	  relapse).	  In	  terms	  of	  relapse	  to	  problem	  behavior,	  both	  reinstatement	  and	  renewal	  have	  been	  widely	  applied	  as	  models	  of	  relapse	  to	  drug	  seeking;	  however,	  only	  two	  studies	  have	  used	  resurgence	  as	  a	  model	  of	  drug	  relapse.	  Therefore,	  much	  of	  what	  is	  known	  in	  the	  basic	  literature	  about	  relapse	  to	  drug	  seeking,	  and	  its	  underlying	  neuropharmacology,	  comes	  from	  studies	  using	  these	  other	  two	  models.	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Reinstatement	  is	  the	  most	  widely	  used	  model	  of	  relapse	  (see	  Shaham	  et	  al.,	  2003).	  Like	  resurgence,	  reinstatement	  is	  a	  three-­‐phase	  procedure.	  First,	  an	  arbitrary	  response	  is	  trained	  and	  maintained	  by	  contingent	  drug	  deliveries.	  Second,	  that	  response	  is	  placed	  on	  extinction	  and	  contingent	  drug	  deliveries	  are	  withheld	  until	  the	  animal	  stops	  responding	  or	  responds	  at	  a	  low	  predetermined	  rate.	  Finally,	  exposure	  to	  certain	  stimuli	  results	  in	  increased	  levels	  of	  the	  previously	  drug-­‐maintained	  response.	  The	  stimuli	  that	  reliably	  reinstate	  drug	  seeking	  include	  re-­‐exposure	  to	  the	  previously	  self-­‐administered	  drug	  (de	  Wit	  &	  Stewart,	  1981),	  drug-­‐associated	  cues	  (See,	  2002;	  Weiss	  et	  al.,	  2001),	  or	  certain	  stressors	  (Shaham	  &	  Stewart,	  1995).	  The	  widespread	  use	  of	  this	  model	  is	  likely	  based	  on	  the	  variety	  of	  stimuli	  that	  are	  used	  to	  induce	  drug	  seeking	  within	  the	  preparation.	  Renewal,	  also	  a	  three-­‐phase	  procedure,	  has	  recently	  gained	  popularity	  within	  the	  drug	  relapse	  literature	  (see	  Crombag	  et	  al.,	  2008).	  	  Renewal	  is	  a	  context-­‐based	  manipulation	  in	  which	  drug	  availability	  changes	  as	  a	  function	  of	  background	  contextual	  stimuli	  (Crombag	  et	  al.,	  2002).	  	  First,	  drug	  is	  self-­‐administered	  in	  the	  presence	  of	  one	  set	  of	  distinct	  contextual	  stimuli	  (e.g.,	  olfactory,	  visual,	  and	  tactile).	  Next,	  the	  drug-­‐maintained	  response	  is	  extinguished	  in	  the	  presence	  of	  a	  distinctly	  different	  set	  of	  stimuli	  until	  responding	  ceases	  or	  falls	  to	  a	  low	  level.	  Finally,	  the	  response	  previously	  maintained	  by	  drug	  increases	  in	  frequency	  upon	  return	  to	  the	  context	  in	  which	  drug	  was	  originally	  available.	  Like	  resurgence,	  circumstances	  similar	  to	  those	  modeled	  in	  reinstatement	  and	  renewal	  preparations	  can	  produce	  relapse	  in	  human	  populations.	  For	  instance,	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Chornock,	  Stitzer,	  Gross,	  and	  Leischow	  (1992)	  found	  that	  smoking	  four	  cigarettes	  subsequent	  to	  a	  four-­‐day	  period	  of	  paid	  abstinence	  from	  smoking	  resulted	  in	  increased	  likelihood	  of	  relapse	  to	  smoking,	  relative	  to	  a	  group	  who	  was	  not	  forced	  to	  smoke	  cigarettes.	  Regarding	  cue	  exposure,	  exposure	  to	  drug	  associated	  cues	  increases	  craving	  (Childress	  et	  al.,	  1993),	  which	  is	  correlated	  with	  actual	  drug	  use	  (Tiffany,	  1990).	  Stressful	  life	  events	  are	  also	  associated	  with	  drug	  taking	  and	  relapse	  (see	  Sinha,	  2001).	  Finally,	  contextual	  change	  also	  appears	  to	  produce	  relapse	  in	  human	  drug	  users	  in	  that	  individuals	  can	  successfully	  abstain	  from	  drug	  use	  in	  inpatient	  detoxification	  programs,	  but	  tend	  to	  relapse	  once	  they	  return	  to	  their	  home	  environments	  (Hunt,	  Barnett,	  &	  Branch,	  1971).	  
Selected	  Neuropharmacology	  
The	  Quick	  et	  al.	  (2011)	  study	  described	  earlier	  also	  examined	  the	  role	  of	  dopamine	  D1	  receptors	  in	  resurgence	  of	  cocaine	  seeking.	  Quick	  and	  colleagues	  injected	  a	  separate	  group	  of	  animals	  with	  the	  dopamine	  D1	  antagonist	  SCH	  23390	  prior	  to	  resurgence	  sessions	  and	  found	  that	  antagonism	  of	  D1	  receptors	  blocked	  resurgence	  of	  cocaine	  seeking.	  Dopamine	  D1	  receptor	  antagonism	  also	  blocks	  drug	  seeking	  in	  certain	  types	  of	  reinstatement	  preparations	  (e.g.,	  Alleweireldt	  et	  al.,	  2002;	  Capriles	  et	  al.,	  2003;	  Norman	  et	  al.,	  1999)	  and	  in	  renewal	  preparations	  (Crombag	  et	  al.,	  2002),	  so	  the	  Quick	  et	  al.	  results	  provide	  preliminary	  evidence	  that	  resurgence	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shares	  common	  neuropharmacology	  with	  drug	  seeking	  observed	  in	  these	  other	  two	  models.	  A	  considerable	  amount	  of	  research	  has	  investigated	  the	  neuropharmacology	  of	  drug	  seeking	  in	  reinstatement	  (see	  Bossert	  et	  al.,	  2005;	  Shalev	  et	  al.,	  2002)	  and	  renewal	  preparations	  (see	  Crombag	  et	  al.,	  2008),	  but	  only	  Quick	  et	  al.	  (2011)	  have	  attempted	  such	  a	  study	  with	  the	  resurgence	  model.	  Because	  dopamine	  D1	  antagonists	  block	  relapse	  to	  drug	  seeking	  in	  reinstatement	  and	  renewal	  preparations,	  attenuation	  of	  resurgence	  by	  SCH	  23390	  in	  the	  Quick	  et	  al.	  study	  suggests	  overlapping	  neuropharmacology	  of	  resurgence,	  reinstatement,	  and	  renewal.	  Therefore,	  other	  neural	  systems	  implicated	  in	  reinstatement	  and	  renewal	  may	  also	  play	  a	  role	  in	  resurgence.	  
Dopamine	  D2	  Receptors	  There	  are	  five	  known	  types	  of	  dopamine	  receptors:	  D1-­‐5	  (Vallone,	  Picetti,	  &	  Borrelli,	  2000).	  The	  dopamine	  D1-­‐like	  family	  of	  receptors	  (D1	  and	  D5	  receptors)	  increases	  cyclic	  adenosine	  monophosphate	  (cAMP)	  concentrations	  while	  the	  D2-­‐like	  family	  (D2-­‐D4	  receptors)	  inhibits	  cAMP	  formation;	  cAMP	  formation	  is	  necessary	  for	  amplification	  of	  intracellular	  signaling	  (Vallone	  et	  al.,	  2000).	  Drug	  abuse	  and	  relapse	  research	  has	  generally	  focused	  on	  the	  involvement	  of	  dopamine	  D1-­‐D3	  receptor	  subtypes	  due	  to	  their	  distribution	  within	  relevant	  brain	  systems	  and	  availability	  of	  selective	  ligands	  (Heidbreder	  &	  Newman,	  2010;	  see	  Self,	  2010).	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As	  noted	  earlier,	  Quick	  et	  al.	  (2011)	  found	  that	  the	  dopamine	  D1	  receptor	  antagonist	  SCH	  23390	  blocks	  resurgence	  of	  cocaine	  seeking.	  Dopamine	  D1	  receptors	  also	  appear	  to	  play	  a	  role	  in	  various	  types	  of	  reinstatement	  (Alleweireldt	  et	  al.,	  2002;	  Capriles	  et	  al.,	  2003;	  Norman	  et	  al.,	  1999),	  as	  well	  as	  renewal	  of	  drug	  seeking	  (Bossert,	  Poles,	  Wihbey,	  Koya,	  &	  Shaham,	  2007;	  Crombag	  et	  al.,	  2002;	  Hamlin,	  Blatchford,	  &	  McNally,	  2007).	  The	  dopamine	  D2	  receptor	  also	  appears	  to	  play	  a	  significant	  role	  across	  different	  models	  of	  relapse.	  Systemic	  administration	  of	  dopamine	  D2	  antagonists	  blocks	  reinstatement	  induced	  by	  re-­‐exposure	  to	  the	  previously	  self-­‐administered	  drug	  (Ettenberg,	  1990;	  Khroyan,	  Barrett-­‐Larimore,	  Rowlett,	  &	  Spealman,	  2000;	  Schenk	  &	  Gittings,	  2003;	  Shaham	  &	  Stewart,	  1996;	  but	  see	  Carati	  &	  Schenk,	  2011).	  Dopamine	  D2	  antagonists	  also	  appear	  to	  block	  renewal	  of	  drug	  seeking	  (Crombag	  et	  al.,	  2002),	  and	  reinstatement	  produced	  by	  exposure	  to	  both	  discrete	  (Gál	  &	  Gyertyán,	  2006;	  Liu	  et	  al.,	  2010;	  Tobin	  et	  al.,	  2009)	  and	  discriminative	  cues	  (Cervo,	  Carnovali,	  Stark,	  &	  Mennini,	  2003;	  Liu	  &	  Weiss,	  2002b;	  but	  see	  McFarland	  &	  Ettenberg,	  1997).	  	  Stress-­‐induced	  reinstatement,	  however,	  does	  not	  appear	  to	  be	  mediated	  by	  activation	  at	  dopamine	  D2	  receptors.	  Systemic	  administration	  of	  dopamine	  D2	  antagonists	  has	  no	  effect	  on	  footshock-­‐	  (Shaham	  &	  Stewart,	  1996)	  or	  food	  deprivation-­‐induced	  (Tobin	  et	  al.,	  2009)	  relapse	  to	  heroin	  seeking.	  Furthermore,	  localized	  injections	  of	  D2	  antagonist	  drugs	  within	  the	  prelimbic	  prefrontal	  cortex	  and	  orbitofrontal	  cortex	  have	  no	  effect	  on	  footshock-­‐induced	  reinstatement	  of	  cocaine	  seeking	  (Capriles	  et	  al.,	  2003).	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   Similar	  patterns	  emerge	  in	  the	  results	  of	  studies	  that	  have	  examined	  relapse	  to	  food	  seeking.	  Administration	  of	  a	  dopamine	  D2	  antagonist	  blocks	  food-­‐primed	  reinstatement	  in	  a	  runway	  task	  (Chausmer	  &	  Ettenberg,	  1997;	  Horvitz	  &	  Ettenberg,	  1988).	  Interestingly,	  there	  is	  evidence	  that	  D2	  antagonists	  potentiate	  (Ball,	  Combs,	  &	  Beyer,	  2011)	  or	  have	  no	  effect	  on	  discrete	  cue-­‐induced	  reinstatement	  of	  food	  seeking	  (Gál	  &	  Gyertyán,	  2006),	  but	  appear	  to	  block	  renewal	  of	  food	  seeking	  (Rauhut,	  Fenton,	  &	  Bardo,	  2010).	  To	  my	  knowledge,	  no	  studies	  have	  yet	  examined	  how	  D2	  antagonists	  affect	  stress-­‐induced	  reinstatement	  of	  food	  seeking.	  	   The	  results	  of	  studies	  examining	  the	  role	  of	  dopamine	  D2	  antagonism	  with	  respect	  to	  drug	  seeking	  largely	  mirror	  those	  of	  D1	  receptor	  antagonism	  with	  the	  exception	  of	  stress-­‐induced	  reinstatement.	  If	  resurgence,	  renewal,	  and	  drug-­‐	  and	  cue-­‐induced	  reinstatement	  models	  share	  common	  neuropharmacology,	  then	  D2	  receptor	  antagonists	  should	  have	  some	  effect	  on	  resurgence.	  
Adrenergic	  α2	  Receptors	  Norepinephrine	  levels	  typically	  increase	  in	  response	  to	  various	  stressors	  (Bremner,	  Krystal,	  Southwick,	  &	  Charney,	  1996),	  and	  accordingly,	  adrenergic	  transmission	  has	  been	  one	  of	  the	  primary	  neuropharmacological	  targets	  in	  research	  on	  stress-­‐induced	  reinstatement	  (see	  Shaham,	  Erb,	  &	  Stewart,	  2000).	  Administration	  of	  α2	  agonists	  blocks	  shock-­‐induced	  reinstatement	  of	  cocaine	  (Erb	  et	  al.,	  2000),	  heroin	  (Shaham	  et	  al.,	  2000),	  alcohol	  (Lê	  et	  al.,	  2005),	  and	  nicotine	  seeking	  (Zislis	  et	  al.,	  2007).	  Comparable	  results	  have	  been	  reported	  with	  chemical	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stressors.	  For	  instance,	  clonidine	  blocks	  yohimbine-­‐induced	  reinstatement	  of	  cocaine	  (Lee,	  Tiefenbacher,	  Platt,	  &	  Spealman,	  2003;	  but	  see	  Brown,	  Tribe,	  D'souza,	  &	  Erb,	  2009),	  and	  alcohol	  seeking	  	  (Lê,	  Funk,	  Harding,	  Juzytsch,	  &	  Fletcher,	  2009).	  	  The	  effects	  of	  clonidine	  on	  drug-­‐primed	  reinstatement	  are	  somewhat	  less	  conclusive.	  Erb	  and	  colleagues	  (2000)	  reported	  that	  the	  α2	  adrenergic	  receptor	  agonists	  clonidine,	  lofexidine,	  and	  guanabenz	  did	  not	  impact	  drug-­‐primed	  reinstatement	  of	  cocaine	  seeking.	  Platt,	  Rowlett,	  and	  Spealman	  (2007)	  reported	  that	  clonidine	  attenuated	  drug-­‐primed	  reinstatement,	  but	  their	  experimental	  arrangement	  included	  elimination	  of	  cocaine-­‐paired	  cues	  during	  extinction	  and	  subsequent	  reintroduction	  during	  reinstatement;	  therefore,	  it	  is	  not	  entirely	  clear	  if	  clonidine	  blocked	  cue-­‐induced	  or	  drug-­‐induced	  reinstatement.	  Considering	  Erb	  et	  al.	  (2000)	  tested	  three	  different	  α2	  agonists	  and	  each	  was	  ineffective	  in	  blocking	  drug-­‐primed	  reinstatement,	  it	  seems	  unlikely	  that	  α2	  receptors	  are	  involved	  in	  drug-­‐induced	  reinstatement.	  However,	  α2	  receptors	  may	  play	  a	  role	  in	  cue-­‐induced	  reinstatement	  in	  light	  of	  the	  results	  from	  Platt	  et	  al.	  (2007).	  The	  existing	  evidence	  regarding	  the	  effects	  of	  α2	  agonists	  on	  cue-­‐induced	  reinstatement	  are	  conflicting.	  Highfield,	  Yap,	  Grimm,	  Shalev,	  and	  Shaham	  (2001)	  reported	  that	  lofexidine	  was	  ineffective	  in	  reducing	  cue-­‐induced	  reinstatement;	  however,	  lofexidine	  injections	  were	  not	  limited	  to	  reinstatement	  sessions	  and	  were	  administered	  during	  a	  portion	  of	  the	  baseline	  sessions,	  as	  well	  as	  all	  extinction	  and	  reinstatement	  sessions.	  Therefore,	  it	  is	  difficult	  to	  say	  whether	  the	  prolonged	  exposure	  to	  the	  drug	  may	  have	  impacted	  their	  results.	  However,	  Buffalari,	  Baldwin,	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and	  See	  (2012)	  reported	  that	  early	  exposure	  to	  guanfacine	  during	  extinction	  attenuated	  subsequent	  yohimbine-­‐induced	  reinstatement,	  which	  suggests	  that	  prolonged	  exposure	  could	  make	  the	  drug	  even	  more	  effective	  at	  reducing	  reinstatement.	  In	  what	  may	  be	  the	  most	  convincing	  demonstration	  of	  α2	  agonists	  attenuating	  cue-­‐induced	  reinstatement,	  Smith	  and	  Aston-­‐Jones	  (2011)	  reported	  that	  the	  α2	  agonists	  clonidine,	  UK-­‐14,304,	  and	  guanfacine	  decreased	  cue-­‐induced	  reinstatement	  of	  cocaine	  seeking	  when	  administration	  was	  limited	  only	  to	  reinstatement	  sessions.	  	  Few	  studies	  have	  examined	  the	  effects	  of	  α2	  agonists	  on	  relapse	  to	  food	  seeking,	  but	  various	  α2	  agonists	  have	  shown	  to	  be	  ineffective	  in	  reducing	  yohimbine-­‐induced	  reinstatement	  of	  food	  seeking	  (Lê	  et	  al.,	  2011;	  Nair,	  Adams-­‐Deutsch,	  Epstein,	  &	  Shaham,	  2009).	  It	  is	  worth	  nothing	  that	  yohimbine	  is	  a	  relatively	  unique	  stressor	  in	  that	  more	  commonly	  used	  stressors	  (e.g.,	  shock)	  do	  not	  produce	  relapse	  to	  food	  seeking	  (Ahmed	  &	  Koob,	  1997),	  whereas	  yohimbine	  does	  (Ghitza,	  Gray,	  Epstein,	  Rice,	  &	  Shaham,	  2006).	  Like	  dopamine	  D2	  receptors,	  adrenergic	  α2	  receptors	  appear	  to	  be	  involved	  in	  more	  than	  one	  type	  of	  relapse.	  Although	  α2	  agonists	  do	  not	  appear	  to	  impact	  priming	  reinstatement,	  and	  have	  not	  yet	  been	  tested	  in	  renewal	  arrangement,	  there	  is	  evidence	  that	  they	  are	  involved	  in	  both	  stress-­‐	  and	  cue-­‐induced	  reinstatement.	  Therefore,	  it	  is	  likely	  that	  these	  receptors	  are	  involved	  in	  resurgence,	  as	  well.	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CHAPTER	  III	  EXPERIMENT	  1:	  THE	  ROLE	  OF	  DOPAMINE	  D2	  RECEPTORS	  IN	  RESURGENCE	  
Purpose	  
Resurgence	  procedures	  in	  which	  extinction	  of	  an	  alternative	  response	  produces	  the	  reappearance	  of	  an	  extinguished	  response	  are	  especially	  relevant	  in	  clinical	  relapse,	  but	  little	  is	  known	  about	  the	  neuropharmacology	  of	  resurgence	  except	  that	  dopamine	  D1	  receptors	  appear	  to	  play	  a	  critical	  role.	  Dopamine	  D1	  receptors	  are	  also	  involved	  in	  reinstatement	  and	  renewal	  preparations,	  suggesting	  common	  neurobiology.	  The	  dopamine	  D2	  receptor	  is	  also	  implicated	  in	  reinstatement	  and	  renewal,	  but	  has	  not	  yet	  been	  examined	  in	  resurgence.	  Thus,	  the	  role	  of	  dopamine	  D2	  receptors	  in	  resurgence	  was	  examined	  via	  administration	  of	  a	  dopamine	  D2	  receptor	  antagonist	  raclopride.	  Rats	  responded	  in	  a	  resurgence	  procedure	  in	  which	  a	  target	  lever	  press	  produced	  food	  deliveries	  during	  Phase	  I,	  the	  lever	  press	  was	  then	  placed	  on	  extinction	  while	  an	  alternative	  nose	  poke	  produced	  food	  deliveries	  during	  Phase	  II,	  and	  finally	  the	  alternative	  nose	  poke	  was	  also	  placed	  on	  extinction	  while	  the	  target	  lever	  remained	  on	  extinction.	  Separate	  groups	  of	  animals	  were	  injected	  with	  vehicle	  or	  one	  of	  two	  doses	  of	  the	  dopamine	  D2	  receptor	  antagonist	  raclopride	  prior	  to	  each	  of	  the	  five	  Phase	  III	  sessions.	  Responding	  was	  compared	  in	  the	  last	  Phase	  II	  and	  first	  Phase	  III	  sessions,	  as	  well	  as	  across	  Phase	  III	  sessions,	  to	  explore	  the	  effects	  of	  raclopride	  on	  resurgence.	  The	  results	  of	  the	  study	  provide	  valuable	  information	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regarding	  the	  underlying	  neural	  mechanisms	  of	  resurgence,	  which	  has	  seen	  little	  attention	  in	  the	  relapse	  literature,	  relative	  to	  reinstatement	  and	  renewal.	  	  
Method	  
Subjects	  	   Twenty-­‐four	  experimentally	  naïve	  male	  Long-­‐Evans	  rats	  (Charles	  River,	  Portage,	  Michigan,	  USA)	  approximately	  90	  days	  old	  upon	  arrival	  in	  the	  experimental	  facility	  were	  used	  in	  the	  experiment.	  The	  animals’	  free-­‐feeding	  weights	  were	  established	  over	  a	  period	  of	  approximately	  14	  days	  after	  arrival	  in	  the	  experimental	  facility.	  Subsequently,	  rats	  were	  maintained	  via	  supplemental	  feedings	  at	  approximately	  80%	  of	  their	  free-­‐feeding	  weights	  throughout	  the	  experiment.	  Rats	  were	  housed	  individually	  with	  free	  access	  to	  water	  in	  a	  temperature-­‐controlled	  room	  with	  a	  12:12h	  light/dark	  cycle	  (lights	  on	  at	  7:00	  AM).	  Experimental	  sessions	  took	  place	  at	  approximately	  the	  same	  time	  each	  day	  during	  the	  light	  cycle.	  
Apparatus	  MED-­‐Associates	  (1999)	  programming	  and	  interface	  controlled	  all	  experimental	  events	  and	  data	  recording.	  Four	  MED-­‐Associates	  modular	  operant	  chambers	  (30	  cm	  ×	  24	  cm	  ×	  21	  cm)	  housed	  in	  sound-­‐attenuating	  cubicles	  were	  used.	  The	  chambers	  were	  composed	  of	  two	  Plexiglas	  walls,	  and	  two	  aluminum	  walls	  opposite	  one	  another.	  On	  the	  back	  wall	  of	  all	  chambers	  were	  five	  evenly	  spaced	  apertures,	  each	  containing	  a	  yellow	  light	  emitting	  diode	  (LEDs),	  as	  well	  as	  a	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photobeam	  capable	  of	  detecting	  head	  entries	  (i.e.,	  nose	  pokes).	  Centered	  on	  the	  opposite	  wall	  was	  a	  recessed	  receptacle	  (5	  cm	  ×	  5	  cm)	  in	  which	  45-­‐mg	  pellets	  were	  delivered.	  Pellet	  deliveries	  were	  accompanied	  by	  an	  audible	  click	  and	  lit	  receptacle.	  Levers	  to	  the	  left	  and	  right	  of	  the	  pellet	  receptacle	  were	  retractable,	  and	  above	  each	  of	  those	  levers	  was	  a	  lamp	  (2.5	  cm	  diameter).	  Each	  chamber	  was	  also	  equipped	  with	  a	  house	  light	  for	  general	  illumination,	  as	  well	  as	  a	  Sonalert	  (2900±	  500	  Hz,	  75–85	  dB)	  for	  producing	  tones.	  	  
Drug	   The	  dopamine	  D2	  receptor	  antagonist	  raclopride	  was	  used.	  Separate	  groups	  of	  animals	  (n	  =	  8)	  received	  0	  (vehicle),	  50,	  or	  100	  μg/kg	  of	  the	  drug.	  These	  doses	  have	  been	  used	  in	  previous	  studies	  to	  attenuate	  renewal	  (Crombag	  et	  al.,	  2002)	  and	  cue-­‐induced	  reinstatement	  (Liu	  &	  Weiss,	  2002b;	  Tobin	  et	  al.,	  2009),	  but	  not	  stress-­‐induced	  reinstatement	  (Tobin	  et	  al.,	  2009).	  Raclopride	  was	  dissolved	  in	  a	  sterile	  0.9%	  saline	  solution.	  Saline	  or	  raclopride	  was	  administered	  subcutaneously	  at	  an	  injection	  volume	  of	  1	  ml/kg	  20	  minutes	  prior	  to	  experimental	  sessions.	  	  
Procedure	  
Training.	  Rats	  experienced	  a	  single	  30-­‐min	  session	  of	  magazine	  training	  in	  which	  pellets	  were	  delivered	  according	  to	  a	  variable	  time	  (VT)	  60-­‐s	  schedule.	  The	  levers	  were	  extended	  into	  the	  chambers,	  but	  the	  lever	  lights	  and	  house	  lights	  remained	  off.	  An	  audible	  click	  and	  3-­‐s	  illumination	  of	  the	  pellet	  receptacle	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accompanied	  pellet	  deliveries	  during	  training	  and	  throughout	  the	  experiment.	  In	  two	  additional	  sessions,	  pellets	  were	  available	  for	  lever	  pressing	  according	  to	  fixed	  ratio	  (FR)	  1	  schedule.	  One	  lever	  produced	  pellets	  when	  pressed	  (i.e.,	  the	  target	  lever),	  while	  the	  other	  lever	  had	  no	  programmed	  consequences	  (i.e.,	  inactive	  lever).	  The	  light	  above	  the	  target	  lever	  was	  lit	  and	  the	  location	  of	  the	  target	  lever	  (left	  or	  right)	  was	  counterbalanced	  across	  subjects.	  	  
Phase	  I.	  During	  Phase	  I,	  pellets	  were	  delivered	  contingent	  on	  target	  lever	  presses	  according	  to	  a	  variable	  interval	  (VI)	  45-­‐s	  schedule	  in	  30-­‐min	  sessions	  timed	  exclusive	  of	  3-­‐s	  pellet	  deliveries.	  Phase	  I	  lasted	  20	  sessions.	  At	  the	  end	  of	  Phase	  I,	  rats	  were	  assigned	  to	  one	  of	  two	  experimental	  groups	  (n	  =	  8	  per	  raclopride	  dose)	  or	  the	  control	  group	  (n	  =	  8)	  while	  matching	  for	  mean	  response	  rates	  during	  the	  final	  3	  sessions	  of	  Phase	  I.	  Each	  drug	  dose	  was	  examined	  within	  a	  separate	  group	  of	  animals	  based	  on	  previous	  findings	  demonstrating	  variations	  across	  repeated	  resurgences	  (Lieving	  &	  Lattal,	  2003).	  
Phase	  II.	  Next,	  lever	  presses	  were	  extinguished	  and	  no	  longer	  produced	  pellet	  deliveries.	  Occurring	  in	  conjunction	  with	  extinction	  of	  the	  lever	  press,	  the	  center	  nose	  poke	  at	  the	  rear	  of	  the	  chamber	  was	  lit	  because	  it	  was	  equidistant	  from	  the	  left	  and	  right	  levers.	  The	  first	  head	  entry	  into	  this	  poke	  in	  the	  first	  session	  of	  Phase	  II	  resulted	  in	  a	  pellet	  delivery,	  and	  afterward	  pellets	  were	  delivered	  according	  to	  a	  VI	  10-­‐s	  schedule.	  These	  contingencies	  remained	  in	  effect	  for	  10	  sessions,	  and	  were	  identical	  for	  all	  groups.	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Phase	  III.	  During	  the	  next	  five	  sessions,	  both	  the	  lever	  and	  poke	  responses	  were	  extinguished	  and	  had	  no	  programmed	  consequences	  for	  all	  groups.	  As	  noted	  earlier,	  the	  groups	  received	  subcutaneous	  injections	  of	  0	  (vehicle),	  50,	  or	  100	  μg/kg	  raclopride	  20	  min	  prior	  to	  Phase	  III	  sessions.	  	  
Results	  
Phase	  I	  All	  animals	  acquired	  the	  target	  lever	  press	  response	  during	  training	  sessions,	  and	  responding	  proceeded	  normally	  throughout	  Phase	  I.	  Subjects	  were	  then	  assigned	  to	  one	  of	  three	  treatment	  groups	  (0,	  50,	  or	  100	  μg	  raclopride)	  so	  as	  to	  match	  average	  (last	  3)	  baseline	  response	  rates	  on	  the	  target	  lever	  across	  groups.	  The	  top	  portion	  of	  Table	  1	  displays	  mean	  (Standard	  Error	  of	  the	  Mean;	  SEM)	  target	  (lever	  associated	  with	  food	  during	  Phase	  I),	  inactive	  (lever	  never	  associated	  with	  food),	  alternative	  (center	  poke	  associated	  with	  food	  during	  Phase	  II),	  and	  other	  (4	  pokes	  never	  associated	  with	  food)	  response	  rates	  (responses	  per	  minute),	  as	  well	  as	  reinforcer	  rates	  for	  the	  three	  treatment	  groups	  across	  the	  final	  3	  Phase	  I	  sessions.	  Rates	  on	  the	  target	  lever	  did	  not	  vary	  systematically	  across	  groups,	  F(2,21)	  =	  0.00,	  p	  =	  1.00,	  and	  all	  other	  responses	  occurred	  similarly	  at	  low	  rates	  across	  the	  groups.	  Rates	  of	  food	  delivery	  also	  did	  not	  vary	  systematically	  across	  groups,	  F(2,21)	  =	  .52,	  p	  =	  .600,	  and	  were	  close	  to	  the	  programmed	  rate	  of	  reinforcement	  of	  1.33	  foods	  per	  minute.	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Phase	  II	  The	  bottom	  portion	  of	  Table	  1	  shows	  response	  and	  reinforcer	  rates	  averaged	  over	  the	  last	  3	  sessions	  of	  Phase	  II.	  The	  extinction	  contingencies	  in	  effect	  on	  the	  target	  lever	  reduced	  response	  rates	  to	  similarly	  low	  levels	  across	  groups,	  F(2,21)	  =	  	  .71,	  p	  =	  .502.	  Reinforcement	  of	  the	  alternative	  poke	  response	  was	  effective	  in	  increasing	  rates	  of	  responding,	  which	  were	  higher	  in	  the	  50	  μg	  group,	  but	  were	  not	  significantly	  different	  across	  groups,	  F(2,21)	  =	  .32,	  p	  =	  .731.	  Phase	  II	  was	  also	  associated	  with	  decreased	  rates	  of	  responding	  on	  the	  inactive	  lever,	  and	  increased	  
Table	  1	  
	  
Mean	  (SEM)	  Response	  and	  Food	  Rates	  Averaged	  over	  the	  Final	  Three	  
Sessions	  of	  Phase	  I	  and	  Phase	  II	  for	  Rats	  in	  Experiment	  1	  
	  	  
Group0'μg 50'μg 100'μgPhase'ITarget 38.03'(10.31) 38.35'(6.54) 38.22'(7.04)Alt 0.02'(0.01) 0.06'(0.04) 0.06'(0.03)Inactive 1.15'(0.58) 1.38'(0.43) 1.02'(0.23)Other 0.11'(0.04) 0.25'(0.17) 0.33'(0.19)Foods 1.24'(0.02) 1.22'(0.01) 1.23'(0.01)Phase'IITarget 2.53'(0.79) 2.29'(0.49) 1.63'(0.25)Alt 50.93'(15.02) 65.61'(18.39) 49.14'(14.37)Inactive 0.86'(0.33) 0.55'(0.13) 0.48'(0.13)Other 7.43'(2.36) 4.49'(1.21) 6.25'(1.87)Foods 4.70'(0.25) 4.57'(0.32) 4.62'(0.26)
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rates	  of	  response	  in	  the	  other	  pokes.	  The	  richer	  VI	  (10-­‐s	  in	  Phase	  II	  versus	  45-­‐s	  in	  Phase	  I)	  produced	  more	  frequent	  reinforcement	  than	  in	  Phase	  I,	  and	  although	  the	  groups	  fell	  short	  of	  the	  programmed	  reinforcement	  rate	  of	  6	  pellets	  per	  minute,	  all	  groups	  earned	  comparable	  rates	  of	  pellet	  deliveries,	  F(2,21)	  =	  .04,	  p	  =	  .943.	  	  
Phase	  III	  
Resurgence	  in	  first	  Phase	  III	  session.	  Figure	  1	  shows	  the	  effects	  of	  raclopride	  on	  response	  rates	  in	  the	  first	  session	  of	  Phase	  III	  relative	  to	  the	  last	  session	  of	  Phase	  II.	  Data	  for	  the	  target	  lever,	  inactive	  lever,	  and	  all	  other	  nose	  pokes	  (i.e.,	  the	  pokes	  that	  did	  not	  produce	  alternative	  reinforcers	  during	  Phase	  II)	  are	  displayed	  to	  demonstrate	  that	  the	  extinction	  contingencies	  introduced	  during	  Phase	  III	  produced	  food	  seeking	  (i.e.,	  elevated	  responding	  on	  the	  target	  lever)	  rather	  than	  general	  activation	  (i.e.,	  increased	  activity	  on	  responses	  with	  no	  prior	  history	  of	  reinforcement).	  Separate	  mixed	  model	  ANOVAs	  were	  conducted	  for	  each	  response	  with	  Phase	  as	  a	  within-­‐subjects	  factor	  and	  Dose	  as	  a	  between-­‐subjects	  factor.	  	  The	  top	  panel	  of	  Figure	  1	  shows	  response	  rates	  on	  the	  target	  lever.	  With	  the	  exception	  of	  the	  100	  μg	  group,	  response	  rates	  were	  higher	  during	  Phase	  III,	  and	  raclopride	  dose-­‐dependently	  reduced	  the	  amount	  of	  resurgence	  on	  the	  target	  lever.	  The	  mixed	  ANOVA	  supported	  this	  interpretation,	  yielding	  significant	  main	  effects	  of	  Phase,	  F(1,21)	  =	  11.61,	  p	  =	  .003,	  and	  Dose,	  F(2,21)	  =	  5.75,	  p	  =	  .010,	  as	  well	  as	  a	  	  significant	  interaction,	  F(2,21)	  =	  7.72,	  p	  =	  .003.	  Fisher’s	  Least	  Significant	  Difference	  (LSD)	  test	  indicated	  that	  the	  0	  and	  100	  µg	  groups	  differed	  significantly.	  To	  follow-­‐up	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the	  significant	  interaction,	  paired	  t-­‐tests	  were	  performed	  to	  compare	  the	  effect	  of	  Phase	  at	  each	  Dose.	  These	  tests	  indicated	  that	  the	  significant	  interaction	  arose	  from	  significant	  resurgence	  occurring	  in	  the	  0	  μg	  group,	  t(7)	  =	  -­‐5.35,	  p	  =	  .022,	  but	  neither	  the	  50	  μg	  group,	  t(7)	  =	  -­‐1.16,	  p	  =	  .286,	  nor	  the	  100	  μg	  group,	  t(7)	  =	  1.59,	  p	  =	  .157.	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Thus,	  elimination	  of	  alternative	  reinforcement	  produced	  resurgence	  on	  the	  target	  lever,	  but	  only	  in	  the	  saline	  group,	  indicating	  that	  raclopride	  suppressed	  resurgence.	  	  The	  middle	  and	  bottom	  panels	  of	  Figure	  1	  show	  response	  rates	  on	  the	  inactive	  lever	  and	  all	  other	  nose	  pokes,	  respectively.	  Again,	  these	  response	  rates	  were	  analyzed	  to	  rule	  out	  the	  possibility	  that	  resurgence	  on	  the	  target	  lever	  was	  accompanied	  by	  increases	  in	  responses	  with	  no	  history	  of	  reinforcement,	  indicative	  of	  general	  activation.	  The	  middle	  portion	  of	  Figure	  1	  shows	  response	  rates	  on	  the	  inactive	  lever.	  Inactive	  response	  rates	  were	  similar	  across	  groups	  and	  phases	  with	  the	  exception	  of	  the	  100	  μg	  group,	  which	  showed	  suppressed	  responding	  during	  Phase	  III.	  However,	  the	  mixed	  model	  ANOVA	  indicated	  that	  these	  differences	  were	  not	  significant,	  Phase	  F(1,21)	  =	  2.52,	  p	  =	  .127,	  Dose	  F(2,21)	  =	  2.30,	  p	  =	  .125,	  Interaction	  F(2,21)	  =	  1.44,	  p	  =	  .260.	  Thus,	  Phase	  III	  was	  not	  associated	  with	  increased	  inactive	  lever	  pressing.	  The	  bottom	  panel	  of	  Figure	  1	  shows	  response	  rates	  on	  all	  other	  nose	  pokes.	  Rates	  of	  responding	  in	  the	  other	  nose	  pokes	  were	  similar	  at	  the	  end	  of	  Phase	  II,	  and	  decreased	  during	  Phase	  III,	  which	  was	  supported	  by	  the	  mixed	  ANOVA	  yielding	  a	  significant	  main	  effect	  of	  Phase,	  F(1,21)	  =	  19.31,	  p	  <	  .001.	  Although	  raclopride	  appeared	  to	  suppress	  rates	  of	  other	  pokes	  in	  the	  50	  and	  100	  μg	  groups	  relative	  to	  the	  0	  μg	  group,	  the	  main	  effect	  of	  Dose,	  F(2,21)	  =	  1.93,	  p	  =	  .170,	  and	  the	  interaction,	  
F(2,21)	  =	  .77,	  p	  =	  .474,	  did	  not	  reach	  significance.	  Unlike	  the	  inactive	  lever	  press,	  in	  which	  there	  was	  no	  significant	  change	  from	  Phase	  II	  to	  III,	  response	  rates	  to	  the	  other	  nose	  pokes	  decreased	  during	  Phase	  III.	  A	  similar	  effect	  was	  observed	  during	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the	  transition	  from	  Phase	  I	  to	  II	  in	  that	  inactive	  lever	  presses	  decreased	  when	  the	  target	  lever	  press	  was	  extinguished.	  These	  results	  suggest	  that	  inactive	  presses	  and	  other	  pokes	  occurred	  because	  of	  generalization	  from	  the	  reinforced	  response	  (i.e.,	  target	  lever	  in	  Phase	  I	  and	  alternative	  poke	  in	  Phase	  II).	  Analysis	  of	  response	  rates	  on	  the	  target	  lever	  along	  with	  the	  two	  responses	  that	  never	  produced	  programmed	  consequences	  showed	  that	  resurgence	  during	  Phase	  III	  occurred	  only	  on	  the	  target	  lever,	  and	  only	  in	  the	  group	  of	  animals	  that	  did	  not	  receive	  raclopride	  injections.	  Therefore,	  raclopride	  effectively	  attenuated	  resurgence	  at	  both	  doses	  tested,	  50	  and	  100	  μg/kg.	  
Across	  Phase	  III	  sessions.	  Injections	  of	  saline	  (0	  μg)	  or	  raclopride	  (50	  or	  100	  μg)	  were	  administered	  before	  each	  of	  the	  five	  Phase	  III	  sessions,	  which	  allowed	  examination	  of	  whether	  repeated	  administration	  of	  raclopride	  alters	  the	  course	  of	  resurgence	  for	  the	  target	  lever	  or	  the	  course	  of	  extinction	  for	  the	  alterative	  poke.	  Figure	  2	  shows	  mean	  (±SEM)	  response	  rates	  for	  the	  target	  and	  alternative	  responses	  across	  all	  five	  sessions	  of	  Phase	  III.	  The	  top	  panel	  of	  Figure	  1	  shows	  the	  course	  of	  resurgence	  across	  sessions	  on	  the	  target	  lever.	  For	  the	  0	  μg	  group,	  target	  lever	  press	  rates	  declined	  steadily	  across	  Phase	  III	  sessions	  and	  were	  higher	  than	  either	  of	  the	  groups	  treated	  with	  raclopride.	  Rates	  for	  the	  50	  μg	  group	  were	  lower	  than	  that	  of	  the	  0	  μg,	  but	  also	  showed	  a	  different	  pattern	  across	  sessions	  in	  that	  the	  lowest	  rates	  occurred	  in	  Session	  2,	  followed	  by	  recovery	  to	  levels	  near	  that	  of	  the	  0	  μg	  group	  by	  the	  end	  of	  Phase	  III.	  Response	  rates	  in	  the	  100	  μg	  group	  remained	  suppressed	  across	  Phase	  III	  sessions.	  A	  mixed	  ANOVA	  with	  Dose	  as	  a	  between-­‐
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subjects	  factor	  and	  Session	  as	  a	  repeated	  factor	  supported	  this	  interpretation,	  yielding	  significant	  main	  effects	  of	  Dose,	  F(2,21)	  =	  16.99,	  p	  <	  .001,	  and	  Session,	  
F(4,84)	  =14.92,	  p	  <	  .001,	  as	  well	  a	  significant	  interaction,	  F(8,84)	  =	  4.34,	  p	  <	  .001.	  Fisher’s	  LSD	  test	  indicated	  each	  pair	  of	  groups	  differed	  significantly.	  The	  significant	  interaction	  arose	  from	  the	  effect	  of	  Session	  reaching	  significance	  within	  the	  0	  [F(4,28)	  =	  10.28,	  p	  <	  .001]	  and	  50	  [F(4,28)	  =	  6.33,	  p	  =	  .001],	  but	  not	  100	  µg	  group	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[F(4,28)	  =	  1.07,	  p	  =	  .391].	  Furthermore,	  the	  effect	  of	  Dose	  was	  significant	  in	  sessions	  1-­‐4	  (all	  p	  values	  <	  .01),	  but	  not	  Session	  5	  [F(2,23)	  =	  2.83,	  p	  =	  .08].	  Rates	  of	  nose	  poking	  across	  Phase	  III	  sessions	  are	  depicted	  in	  the	  bottom	  panel	  of	  Figure	  2.	  Responding	  decreased	  across	  sessions	  for	  the	  0	  μg	  group,	  while	  raclopride	  dose-­‐dependently	  reduced	  nose	  poking	  during	  the	  first	  session	  of	  Phase	  III,	  but	  appeared	  to	  suppress	  responding	  almost	  completely	  throughout	  the	  remaining	  sessions	  in	  both	  groups	  treated	  with	  raclopride.	  A	  mixed	  ANOVA	  supported	  this	  interpretation,	  producing	  significant	  main	  effects	  of	  Dose,	  F(2,21)	  =	  81.99,	  p	  <	  .001,	  and	  Session,	  F(4,84)	  =	  43.28,	  p	  <	  .001,	  as	  well	  as	  a	  significant	  interaction,	  F(8,84)	  =	  12.62,	  p	  <	  .001.	  Fisher’s	  test	  indicated	  that	  rates	  of	  the	  alternative	  poke	  response	  were	  significantly	  suppressed	  in	  both	  raclopride	  groups	  relative	  to	  the	  saline	  control,	  but	  did	  not	  differ	  from	  one	  another.	  	  The	  significant	  interaction	  arose	  because	  Dose	  was	  significant	  at	  each	  session	  (all	  p	  values	  <	  .01)	  due	  to	  both	  groups	  treated	  with	  raclopride	  differing	  significantly	  from	  the	  0	  µg	  control	  group.	  Thus,	  raclopride	  suppressed	  resurgence	  of	  the	  target	  lever	  and	  hastened	  extinction	  of	  the	  alternative	  nose	  poke	  across	  Phase	  III	  sessions	  at	  both	  doses	  tested.	  Slightly	  different	  patterns	  emerged	  between	  the	  two	  responses	  in	  the	  50	  μg	  group.	  Both	  responses	  fell	  to	  very	  low	  levels	  during	  the	  second	  Phase	  III	  session,	  but	  there	  was	  a	  subsequent	  increase	  in	  the	  target	  response,	  whereas	  the	  alternative	  poke	  remained	  suppressed	  almost	  completely.	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Motivational	  versus	  motor	  impairment.	  Raclopride	  suppressed	  resurgence	  on	  the	  target	  lever	  during	  the	  first	  session	  of	  Phase	  III	  and	  throughout	  the	  remaining	  Phase	  III	  sessions;	  however,	  suppressed	  responding	  may	  be	  indicative	  of	  motivational	  or	  motor	  impairments.	  Although	  these	  effects	  are	  difficult	  to	  dissociate	  (see	  Grimm	  et	  al.,	  2011),	  previous	  studies	  have	  used	  a	  variety	  of	  measures	  to	  examine	  the	  effects	  of	  drugs	  on	  motivation	  to	  initiate	  responding,	  motivation	  to	  respond	  throughout	  the	  test	  session,	  and	  ability	  to	  respond	  (Alleweireldt	  et	  al.,	  2002;	  Grimm	  et	  al.,	  2011;	  Quick	  et	  al.,	  2011).	  A	  primary	  aim	  of	  some	  of	  these	  analyses	  is	  to	  determine	  whether	  responding	  under	  the	  influence	  of	  drug	  is	  similar	  to	  responding	  under	  extinction	  conditions.	  Animals	  are	  capable	  of	  responding	  during	  extinction,	  but	  presumably	  do	  not	  because	  there	  is	  no	  motivating	  consequence	  (i.e.	  reinforcement).	  Therefore,	  responding	  that	  resembles	  extinction-­‐like	  responding	  is	  thought	  to	  result	  from	  motivational	  deficits	  and	  not	  motor	  impairment.	  Another	  aim	  of	  these	  analyses	  is	  to	  determine	  whether	  deficits	  are	  specific	  to	  responses	  associated	  with	  reward	  or	  if	  all	  behavior	  occurring	  within	  the	  session	  is	  suppressed.	  Whereas	  response	  reduction	  limited	  to	  behavior	  associated	  with	  reward	  is	  thought	  to	  reflect	  motivational	  impairment,	  nonspecific	  deficits	  are	  thought	  to	  result	  from	  motor	  impairment.	  Analyses	  for	  the	  present	  experiment	  are	  somewhat	  unique	  in	  that	  the	  available	  responses	  in	  the	  chamber	  included	  not	  only	  a	  target	  and	  inactive	  lever,	  but	  also	  an	  alternative	  poke	  and	  other	  inactive	  pokes.	  Analyses	  of	  all	  available	  responses	  were	  needed	  because	  the	  target	  and	  alternative	  were	  associated	  with	  deliveries	  of	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the	  same	  reinforcer	  (i.e.,	  food	  pellets).	  Deficits	  in	  both	  responses	  would	  indicate	  a	  general	  change	  in	  motivation	  for	  food,	  whereas	  deficits	  in	  just	  the	  target	  would	  indicate	  that	  the	  drug	  did	  not	  have	  a	  general	  effect,	  but	  rather	  affected	  motivation	  to	  revert	  to	  a	  previously	  productive	  response.	  	  
Motivation	  to	  initiate	  responding.	  Alleweireldt	  and	  colleagues	  (2002)	  examined	  latency	  to	  the	  first	  target	  response	  as	  an	  index	  of	  motivation	  early	  in	  the	  session.	  The	  top	  panel	  Figure	  3	  shows	  average	  (±SEM)	  latencies	  to	  the	  first	  target	  and	  alternative	  responses	  in	  the	  first	  session	  of	  Phase	  III.	  Latency	  to	  the	  first	  target	  response	  was	  similar	  in	  the	  0	  and	  50	  μg	  groups,	  but	  increased	  dramatically	  in	  the	  100	  μg	  group	  (note	  the	  logarithmic	  y-­‐axis).	  Table	  2	  contains	  individual	  subject	  data	  for	  these	  measures	  and	  shows	  that	  two	  subjects	  in	  particular	  (O7	  and	  P7)	  influenced	  the	  mean	  and	  variation	  of	  the	  target	  latency	  in	  the	  100	  μg	  group.	  Animals	  were	  faster	  to	  initiate	  the	  nose	  poke	  response	  regardless	  of	  group,	  and	  nose	  poke	  latencies	  showed	  less	  variation,	  but	  were	  dose-­‐dependently	  increased	  by	  raclopride.	  A	  mixed	  ANOVA	  with	  Response	  as	  a	  within-­‐subjects	  factor	  and	  Dose	  as	  a	  between-­‐subjects	  factor	  indicated	  a	  nearly	  significant	  main	  effect	  of	  Response,	  F(1,21)	  =	  3.37,	  
p	  =	  .081,	  a	  significant	  main	  effect	  of	  Dose,	  F(1,21)	  =	  3.63,	  p	  =	  .044,	  and	  a	  nearly	  significant	  interaction,	  F(1,21)	  =	  2.92,	  p	  =	  .076.	  Fisher’s	  test	  indicated	  that	  the	  100	  μg	  group	  was	  significantly	  slower	  to	  initiate	  responding	  than	  the	  0	  and	  50	  μg	  groups,	  which	  did	  not	  differ	  from	  one	  another.	  Although	  the	  interaction	  did	  not	  reach	  traditional	  levels	  of	  significance,	  simple	  main	  effects	  ANOVAs	  of	  Dose	  were	  conducted	  for	  each	  response	  to	  explore	  the	  nearly	  significant	  interaction.	  The	  effect	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of	  dose	  was	  nearly	  significant	  for	  the	  target,	  F(2,21)	  =	  3.266,	  p	  =	  .058,	  and	  did	  not	  reach	  significance	  for	  the	  alternative	  poke,	  F(2,21)	  =	  1.950,	  p	  =	  .167.	  Thus,	  latencies	  for	  the	  target	  tended	  to	  be	  greater	  than	  for	  the	  alternative	  nose	  poke,	  but	  this	  is	  not	  surprising	  considering	  the	  nature	  of	  the	  experimental	  manipulation.	  That	  is,	  the	  poke	  was	  reinforced	  in	  the	  prior	  session,	  so	  it	  follows	  that	  subjects	  would	  initiate	  that	  	  
	  	  
Figure	  3.	  Effects	  of	  raclopride	  on	  mean	  (±SEM)	  latencies	  (top	  panel;	  note	  logarithmic	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response	  before	  reverting	  to	  the	  target	  lever,	  which	  was	  reinforced	  more	  remotely	  at	  the	  end	  of	  Phase	  I.	  Furthermore,	  the	  100	  μg	  dose	  of	  raclopride	  significantly	  impacted	  latency	  to	  first	  response,	  but	  tended	  to	  have	  a	  larger	  impact	  on	  the	  target	  lever	  than	  on	  the	  alternative	  nose	  poke.	  In	  a	  similar	  analysis,	  Grimm	  et	  al.	  (2011)	  examined	  the	  number	  of	  responses	  emitted	  during	  the	  first	  2	  minutes	  of	  an	  experimental	  test	  session	  to	  examine	  motivation	  to	  initiate	  responding.	  Average	  (±SEM)	  responses	  emitted	  during	  the	  first	  2	  minutes	  of	  the	  first	  Phase	  III	  session	  are	  shown	  in	  the	  bottom	  panel	  of	  Figure	  3,	  and	  individual	  subject	  data	  for	  these	  measures	  are	  presented	  in	  Table	  2.	  These	  results	  were	  highly	  similar	  to	  those	  of	  the	  latency	  data:	  More	  responses	  to	  the	  alternative	  poke	  occurred	  in	  the	  first	  2	  minutes	  of	  the	  session,	  and	  raclopride	  dose-­‐dependently	  reduced	  early	  responses	  to	  the	  alternative	  nose	  poke,	  but	  appeared	  to	  impact	  the	  target	  lever	  only	  at	  the	  100	  μg	  dose.	  A	  mixed	  ANOVA	  yielded	  significant	  	  main	  effects	  of	  Response,	  F(1,21)	  =	  14.95,	  p	  =	  .001,	  Dose,	  F(1,21)	  =	  4.54,	  p	  =	  .023,	  and	  a	  nearly	  significant	  interaction,	  F(1,21)	  =	  2.80,	  p	  =	  .084.	  Fisher’s	  test	  indicated	  that	  the	  100	  µg	  group	  differed	  from	  the	  0	  µg	  group.	  Again,	  simple	  main	  effects	  ANOVAs	  were	  conducted	  for	  Dose	  at	  each	  response	  because	  the	  interaction	  approached	  significance.	  Raclopride	  had	  significant	  effects	  on	  the	  target	  lever	  presses,	  F(2,21)	  =	  5.43,	  p	  =	  .013,	  and	  alternative	  pokes,	  F(2,21)	  =	  3.77,	  p	  =	  .040.	  Fisher’s	  test	  indicated	  that	  the	  100	  µg	  group	  differed	  from	  both	  the	  0	  and	  50	  µg	  groups	  in	  terms	  of	  target	  presses,	  but	  only	  the	  0	  and	  100	  µg	  groups	  differed	  in	  terms	  of	  early	  alternative	  pokes.	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Not	  surprisingly	  results	  of	  analyses	  on	  responses	  made	  in	  the	  first	  2	  minutes	  largely	  paralleled	  those	  of	  the	  latencies.	  The	  100	  µg	  group	  emitted	  significantly	  fewer	  responses	  in	  the	  first	  2	  minutes	  of	  the	  session.	  Furthermore,	  the	  higher	  dose	  of	  raclopride	  had	  somewhat	  differential	  effects	  on	  the	  two	  responses	  in	  that	  target	  pressing	  was	  significantly	  different	  from	  the	  0	  and	  50	  µg	  groups,	  but	  alternative	  pokes	  were	  different	  from	  only	  the	  0	  µg	  group.	  
Motivation	  across	  the	  session.	  The	  impact	  of	  drugs	  on	  motivation	  throughout	  the	  session	  has	  also	  been	  examined	  to	  dissociate	  motivational	  and	  motor	  impairment.	  Alleweireldt	  and	  colleagues	  (2002)	  calculated	  a	  measure	  of	  persistence	  by	  subtracting	  the	  time	  of	  the	  first	  response	  from	  the	  time	  of	  the	  last	  response	  to	  determine	  the	  duration	  during	  which	  responses	  occurred	  throughout	  the	  session.	  Mean	  (±SEM)	  persistence	  scores	  for	  each	  group	  are	  shown	  for	  the	  target	  and	  alternative	  responses	  in	  Figure	  4,	  and	  individual	  subject	  data	  are	  shown	  in	  Table	  2.	  Persistence	  in	  the	  0	  and	  50	  μg	  groups	  was	  similar,	  but	  was	  lower	  in	  the	  100	  μg	  group.	  Furthermore,	  the	  target	  appeared	  to	  be	  less	  persistent	  than	  the	  alternative	  in	  100	  µg	  group,	  but	  as	  seen	  in	  Table	  2,	  the	  group	  mean	  was	  dragged	  down	  by	  two	  persistence	  scores	  of	  0	  because	  only	  one	  target	  response	  was	  emitted.	  A	  mixed	  ANOVA	  indicated	  significant	  differences	  for	  Dose,	  F(1,21)	  =	  10.49,	  p	  =	  .001,	  but	  not	  Response,	  F(1,21)	  =	  2.63,	  p	  =	  .120,	  nor	  the	  interaction,	  F(1,21)	  =	  2.27,	  p	  =	  .128.	  Fisher’s	  test	  indicated	  that	  responding	  was	  less	  persistent	  in	  the	  100	  μg	  group	  than	  either	  the	  0	  or	  50	  μg	  groups.	  Thus,	  there	  was	  no	  statistical	  support	  for	  raclopride	  differentially	  affecting	  persistence	  of	  the	  two	  responses.	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Quick	  and	  colleagues	  (2011)	  compared	  target	  response	  patterns	  throughout	  the	  last	  Phase	  II	  session	  and	  first	  Phase	  III	  session	  to	  determine	  whether	  drug	  administration	  produced	  responding	  similar	  to	  extinction,	  reasoning	  that	  	  extinction-­‐like	  patterns	  imply	  motivational	  rather	  than	  motor	  deficits.	  Figure	  5	  shows	  the	  effects	  of	  raclopride	  on	  mean	  (±SEM)	  cumulative	  target	  presses	  across	  2-­‐minute	  bins	  of	  the	  last	  Phase	  II	  and	  first	  Phase	  III	  sessions.	  A	  mixed	  ANOVA	  with	  Phase	  and	  Bin	  as	  within-­‐subjects	  factors	  and	  Dose	  as	  a	  between-­‐subjects	  factor	  produced	  a	  significant	  3-­‐way	  interaction,	  F(28,	  294)	  =	  6.86,	  p	  <	  .001,	  along	  with	  all	  other	  2-­‐way	  interactions	  and	  main	  effects	  reaching	  significance.	  To	  explore	  this	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significant	  interaction	  further,	  separate	  Dose	  ×	  Bin	  mixed	  ANOVAs	  were	  conducted	  for	  each	  Phase.	  Cumulative	  target	  presses	  increased	  similarly	  for	  all	  groups	  throughout	  the	  last	  session	  of	  Phase	  II	  as	  indicated	  by	  a	  significant	  main	  effect	  of	  Bin,	  F(14,294)	  =	  24.50,	  p	  <	  .001,	  but	  a	  nonsignificant	  main	  effect	  Dose,	  F(2,21)	  =	  .69,	  
p	  =	  .512,	  and	  nonsignificant	  interaction,	  F(28,294)	  =	  1.00,	  p	  =	  .473.	  Accordingly,	  these	  data	  were	  collapsed	  across	  groups	  in	  Figure	  5	  (open	  diamonds).	  Raclopride	  dose-­‐dependently	  decreased	  cumulative	  target	  response	  during	  Phase	  III	  as	  indicated	  by	  significant	  main	  effects	  of	  Dose,	  F(2,21)	  =	  8.03,	  p	  =	  .003,	  Bin,	  F(14,294)	  =	  39.51,	  p	  <	  .001,	  and	  a	  significant	  interaction,	  F(28,294)	  =	  7.65,	  p	  <	  .001.	  Fisher’s	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test	  indicated	  that	  the	  100	  μg	  group	  differed	  from	  the	  0	  and	  50	  μg	  groups,	  which	  did	  not	  differ	  from	  one	  another.	  Additional	  Phase	  ×	  Bin	  mixed	  ANOVAs	  were	  conducted	  for	  each	  group	  to	  determine	  whether	  raclopride	  produced	  extinction-­‐like	  responding.	  Response	  patterns	  in	  the	  0	  μg	  group	  during	  Phase	  III	  were	  clearly	  different	  as	  indicated	  by	  a	  significant	  main	  effect	  of	  Phase,	  F(1,7)	  =	  15.83,	  p	  =	  .005,	  Bin,	  F(14,98)	  =	  18.10,	  p	  <	  .001,	  and	  a	  significant	  interaction,	  F(14,98)	  =	  23.00,	  p	  <	  .001.	  Cumulative	  target	  presses	  in	  the	  50	  µg	  group	  did	  not	  differ	  markedly	  from	  extinction	  in	  that	  the	  main	  effect	  of	  Phase	  did	  not	  reach	  significance,	  F(1,7)	  =	  1.31,	  p	  =	  .289,	  but	  the	  main	  effect	  of	  Bin,	  F(14,98)	  =	  19.79,	  p	  <	  .001,	  and	  the	  interaction,	  F(14,98)	  =	  2.17,	  p	  =	  .014,	  did	  reach	  significance.	  Cumulative	  target	  presses	  were	  significantly	  suppressed	  in	  the	  100	  µg	  group	  during	  Phase	  III	  as	  indicated	  by	  significant	  main	  effects	  of	  Phase,	  
F(1,7)	  =	  11.29,	  p	  =	  .012,	  and	  Bin,	  F(14,98)	  =	  12.04,	  p	  <	  .001,	  but	  a	  nonsignificant	  interaction,	  F(14,98)	  =	  1.51,	  p	  =	  .120.	  	  In	  summary,	  the	  groups	  did	  not	  differ	  in	  terms	  of	  within-­‐session	  response	  patterns	  during	  the	  last	  session	  of	  Phase	  II,	  but	  raclopride	  dose-­‐dependently	  suppressed	  responding	  during	  the	  first	  Phase	  III	  session,	  and	  significant	  differences	  emerged	  between	  the	  0	  and	  100	  µg	  groups.	  Furthermore,	  cumulative	  target	  presses	  were	  significantly	  suppressed	  relative	  to	  extinction	  in	  Phase	  II	  for	  the	  100	  µg	  group.	  	   Ability	  to	  respond.	  Alleweireldt	  and	  colleagues	  (2002)	  examined	  inter-­‐response	  times	  (IRTs)	  of	  active	  responses	  to	  gauge	  whether	  drug	  administration	  impacted	  subjects’	  ability	  to	  respond.	  The	  top	  panel	  of	  Figure	  6	  shows	  average	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(±SEM)	  IRTs	  for	  the	  target	  lever	  and	  alternative	  pokes	  during	  the	  first	  Phase	  III	  session.	  Table	  2	  displays	  mean	  (Standard	  Deviation;	  SD)	  IRTs	  for	  individual	  subjects,	  as	  well	  as	  the	  number	  of	  responses	  emitted.	  IRTs	  were	  generally	  lower	  for	  the	  alternative	  poke	  (i.e.,	  responding	  was	  more	  frequent).	  The	  50	  μg	  group	  looked	  similar	  to	  the	  0	  μg	  group,	  but	  increases	  in	  IRTs	  for	  both	  responses	  were	  evident	  in	  the	  100	  μg	  group.	  A	  mixed	  ANOVA	  with	  Response	  as	  a	  within-­‐subjects	  factor	  and	  Dose	  as	  a	  between-­‐	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subjects	  factor	  supported	  this	  interpretation,	  producing	  significant	  main	  effects	  of	  Response,	  F(1,21)	  =	  4.52,	  p	  =	  .047,	  and	  Dose,	  F(1,21)	  =	  4.55,	  p	  =	  .024,	  but	  a	  nonsignificant	  interaction,	  F(1,21)	  =	  1.50,	  p	  =	  .248.	  Fisher’s	  tests	  indicated	  that	  the	  100	  μg	  group	  differed	  from	  both	  0	  and	  50	  µg	  groups,	  which	  did	  not	  differ	  from	  one	  another.	  Previous	  studies	  have	  also	  examined	  the	  effects	  of	  drugs	  on	  inactive	  response	  rates	  to	  dissociate	  motor	  from	  motivational	  effects	  because	  these	  rates	  tend	  to	  decrease	  when	  drugs	  produce	  general	  impairment	  (see	  Grimm	  et	  al.,	  2011;	  Quick	  et	  al.,	  2011).	  The	  bottom	  panel	  of	  Figure	  6	  shows	  response	  rates	  on	  the	  inactive	  lever,	  as	  well	  as	  all	  other	  nose	  pokes,	  in	  the	  first	  session	  of	  Phase	  III.	  Table	  2	  shows	  individual	  subject	  data.	  Within	  all	  groups	  more	  responding	  occurred	  to	  the	  other	  pokes	  than	  to	  the	  inactive	  lever.	  Raclopride	  dose-­‐dependently	  reduced	  both	  responses,	  but	  the	  effect	  was	  more	  dramatic	  for	  the	  other	  nose	  pokes.	  Another	  	  mixed	  ANOVA	  with	  Response	  (Inactive	  versus	  Other)	  as	  a	  within-­‐subjects	  factor	  and	  Dose	  as	  a	  between-­‐subjects	  factor	  supported	  this	  interpretation,	  producing	  significant	  main	  effects	  of	  Response,	  F(1,21)	  =	  16.94,	  p	  <	  .001,	  Dose,	  F(1,21)	  =	  10.48,	  
p	  =	  .001,	  and	  a	  significant	  interaction,	  F(1,21)	  =	  7.87,	  p	  =	  .003.	  Simple	  main	  effects	  ANOVAs	  for	  Dose	  were	  then	  conducted	  for	  each	  response.	  Raclopride	  significantly	  impacted	  inactive	  lever	  pressing,	  F(2,21)	  =	  3.75,	  p	  =	  .041,	  and	  other	  nose	  pokes,	  
F(2,21)	  =	  9.81,	  p	  =	  .001.	  Fisher’s	  tests	  indicated	  only	  the	  0	  and	  100	  µg	  groups	  differed	  on	  inactive	  presses,	  whereas	  both	  groups	  treated	  with	  raclopride	  differed	  from	  the	  0	  µg	  group	  in	  terms	  of	  other	  pokes.	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In	  summary,	  the	  100	  µg	  group	  differed	  significantly	  from	  the	  control	  group	  in	  terms	  of	  both	  IRTs	  of	  the	  target	  and	  alternative,	  as	  well	  as	  inactive	  and	  other	  response	  rates.	  These	  deficits	  suggest	  that	  the	  100	  µg/kg	  dose	  of	  raclopride	  affected	  more	  than	  just	  motivation,	  and	  produced	  general	  disruption	  of	  motor	  behavior.	  Although	  rates	  of	  other	  nose	  pokes	  were	  impacted	  at	  the	  50	  µg	  dose,	  this	  group	  of	  animals	  did	  not	  show	  any	  other	  signs	  of	  motor	  impairment.	  
Discussion	  
There	  were	  no	  systematic	  differences	  in	  response	  or	  reinforcer	  rates	  among	  the	  groups	  during	  Phase	  I	  or	  Phase	  II.	  When	  reinforcement	  for	  the	  alternative	  nose	  poke	  response	  was	  discontinued	  during	  Phase	  III,	  administration	  of	  50	  and	  100	  
µg/kg	  raclopride	  reduced	  resurgence	  specific	  to	  the	  target	  lever.	  Raclopride	  also	  altered	  patterns	  of	  decline	  in	  target	  and	  alternative	  responding	  across	  Phase	  III	  sessions.	  Target	  responding	  was	  dose-­‐dependently	  attenuated	  across	  sessions,	  and	  	  each	  pair	  of	  groups	  differed	  from	  one	  another.	  Patterns	  of	  the	  alternative	  poke	  were	  slightly	  different	  in	  that	  response	  rates	  in	  both	  groups	  treated	  with	  raclopride	  were	  almost	  nonexistent	  across	  Phase	  III	  sessions,	  and	  did	  not	  differ	  from	  one	  another,	  but	  differed	  from	  the	  0	  µg	  group.	  Several	  additional	  measures	  were	  examined	  to	  rule	  out	  the	  possibility	  that	  raclopride	  reduced	  resurgence	  by	  interfering	  with	  the	  animals’	  ability	  to	  respond,	  and	  the	  results	  of	  these	  analyses	  are	  summarized	  in	  Table	  3.	  First,	  motivation	  to	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  initiate	  responding	  was	  examined	  via	  two	  measures:	  latency	  to	  the	  first	  response	  and	  number	  of	  responses	  made	  in	  the	  first	  2	  minutes	  of	  the	  session.	  Across	  groups,	  animals	  were	  faster	  to	  initiate	  the	  alternative	  nose	  poke	  than	  the	  target	  lever	  press.	  However,	  the	  100	  µg	  group	  was	  slower	  than	  both	  0	  and	  50	  µg	  groups	  who	  did	  not	  differ,	  and	  the	  target	  was	  slightly	  more	  susceptible	  to	  slowing	  than	  the	  alternative.	  Not	  surprisingly	  given	  the	  latency	  data,	  more	  responding	  occurred	  to	  the	  alternative	  poke	  within	  the	  first	  2	  minutes	  of	  the	  session.	  The	  100	  µg	  group	  emitted	  fewer	  target	  presses	  than	  the	  0	  and	  50	  µg	  groups,	  but	  fewer	  alternative	  pokes	  than	  only	  the	  0	  µ	  group.	  Second,	  the	  persistence	  of	  each	  response	  was	  examined	  by	  calculating	  the	  duration	  of	  the	  session	  in	  which	  responding	  occurred	  (i.e.,	  time	  of	  last	  response	  minus	  time	  of	  first	  response).	  Responding	  was	  less	  persistent	  in	  the	  100	  µg	  group	  
Table	  3	  
Summary	  of	  Statistical	  Comparisons	  Between	  Control	  Group	  (0	  μg)	  and	  
Groups	  Treated	  with	  Raclopride	  and	  (50	  and	  100	  μg)	  for	  Motivational	  
and	  Motor	  Measures	  
	  
	  	  
Target AlternativeMeasure/ 50/μg 100/μg 50/μg 100/μgFirst/III NS * * *Across/III * * * *Latency NS * NS *First/2/min NS * NS *Persistence NS * NS *Cumulative NS * A AIRT NS * NS *Inactive/Other NS * * *
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than	  the	  0	  and	  50	  µg	  groups,	  and	  there	  was	  visual	  evidence	  the	  target	  was	  less	  persistent,	  but	  the	  statistical	  analyses	  did	  not	  support	  this	  conclusion.	  Third,	  cumulative	  target	  patterns	  across	  the	  session	  were	  examined	  to	  determine	  whether	  responding	  was	  “extinction-­‐like”	  (i.e.,	  similar	  to	  Phase	  II).	  Within-­‐session	  response	  patterns	  on	  the	  target	  lever	  were	  significantly	  different	  in	  the	  100	  µg	  group	  than	  the	  0	  and	  50	  µg	  groups.	  Furthermore,	  the	  100	  µg	  group	  displayed	  target	  response	  patterns	  during	  Phase	  III	  that	  were	  significantly	  suppressed	  relative	  to	  Phase	  II.	  Finally,	  the	  animals’	  ability	  to	  respond	  was	  explored	  in	  two	  ways:	  examination	  of	  IRTs	  of	  the	  active	  and	  target	  responses,	  as	  well	  as	  rates	  of	  responses	  never	  associated	  with	  reinforcement	  to	  test	  for	  general	  impairment.	  IRTs	  were	  lower	  for	  the	  alternative	  poke	  (i.e.,	  these	  responses	  occurred	  more	  frequently),	  and	  the	  100	  
µg	  group	  responded	  less	  frequently	  than	  the	  0	  and	  50	  µg	  groups,	  which	  did	  not	  differ.	  More	  other	  pokes	  occurred	  than	  inactive	  lever	  presses	  in	  each	  of	  the	  groups.	  Fewer	  inactive	  presses	  occurred	  in	  the	  100	  µg	  group	  than	  the	  0	  µg	  group,	  but	  both	  raclopride	  groups	  emitted	  fewer	  other	  pokes	  than	  the	  0	  µg	  group.	  Given	  that	  the	  group	  of	  rats	  that	  received	  the	  100	  µg/kg	  dose	  of	  raclopride	  during	  Phase	  III	  showed	  significant	  deficits	  relative	  to	  the	  0	  µg	  group	  in	  every	  single	  measure	  just	  described,	  it	  appears	  that	  a	  general	  disruption	  of	  motor	  behavior	  may	  have	  contributed	  to	  the	  effects	  of	  the	  100	  µg/kg	  dose	  on	  resurgence.	  While	  the	  50	  µg	  group	  showed	  little	  evidence	  of	  motor	  impairment	  in	  the	  measures	  that	  have	  been	  previously	  used	  to	  assess	  motor	  impairment,	  this	  group	  showed	  significant	  deficits	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relative	  to	  the	  0	  µg	  group	  in	  the	  target	  and	  alternative	  responses	  across	  Phase	  III	  sessions.	  Thus,	  there	  is	  strong	  evidence	  for	  motor	  impairment	  at	  the	  100	  µg	  dose,	  but	  the	  evidence	  for	  the	  50	  µg	  group	  is	  more	  ambiguous,	  so	  attenuation	  of	  resurgence	  via	  motor	  impairment	  cannot	  be	  ruled	  out	  at	  either	  dose.	  At	  least	  one	  previous	  study	  has	  reported	  motor	  impairment	  at	  the	  doses	  tested	  in	  the	  present	  study.	  Crombag	  and	  colleagues	  (2002)	  tested	  50	  and	  100	  μg/kg	  raclopride	  on	  contextual	  renewal	  of	  cocaine	  seeking.	  They	  found	  that	  both	  doses	  attenuated	  renewal,	  but	  that	  these	  same	  doses	  also	  reduced	  active	  lever	  pressing	  in	  controls	  animals	  that	  were	  not	  exposed	  to	  the	  manipulation	  that	  induced	  drug	  seeking.	  These	  results	  are	  interesting	  in	  that	  they	  are	  consistent	  with	  Experiment	  1	  with	  respect	  to	  the	  100,	  but	  not	  50	  µg/kg	  dose.	  More	  specifically,	  there	  was	  little	  indication	  of	  motor	  impairment	  in	  the	  50	  µg	  group	  in	  the	  present	  experiment.	  The	  results	  concerning	  motor	  impairment	  in	  the	  100	  µg	  group	  are	  also	  somewhat	  surprising	  in	  of	  light	  previous	  studies	  on	  reinstatement	  that	  have	  used	  the	  same	  or	  higher	  doses	  of	  raclopride	  and	  reported	  little	  or	  no	  evidence	  of	  motor	  impairment.	  For	  instance,	  Shaham	  and	  Stewart	  (1996)	  tested	  the	  effects	  of	  250	  and	  500	  μg/kg	  raclopride	  on	  heroin-­‐	  and	  shock-­‐induced	  reinstatement,	  and	  both	  doses	  blocked	  shock-­‐induced	  reinstatement,	  but	  left	  heroin-­‐induced	  reinstatement	  intact.	  Cervo	  and	  colleagues	  (2003)	  tested	  the	  effects	  of	  30,	  100,	  and	  300	  μg/kg	  raclopride	  on	  cue-­‐induced	  reinstatement	  of	  cocaine	  seeking	  and	  found	  that	  100	  and	  300	  µg/kg	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blocked	  reinstatement	  without	  affecting	  inactive	  lever	  presses.	  Tobin	  and	  colleagues	  (2009)	  tested	  50	  and	  100	  μg/kg	  raclopride	  on	  food	  deprivation-­‐	  and	  cue-­‐induced	  reinstatement	  of	  heroin	  seeking.	  They	  found	  that	  raclopride	  did	  not	  block	  deprivation-­‐induced	  reinstatement,	  but	  dose-­‐dependently	  reduced	  cue-­‐induced	  reinstatement.	  Raclopride	  did	  not	  affect	  inactive	  lever	  pressing	  in	  tests	  of	  either	  type	  of	  reinstatement.	  It	  is	  not	  entirely	  clear	  why	  so	  many	  studies	  have	  successfully	  used	  these	  high	  doses	  of	  raclopride	  in	  the	  absence	  of	  motor	  impairment,	  but	  it	  may	  be	  related	  to	  raclopride’s	  effects	  on	  food-­‐	  versus	  drug-­‐maintained	  responding.	  Previous	  studies	  have	  shown	  that	  raclopride	  may	  impact	  food-­‐maintained	  behavior	  to	  a	  larger	  extent	  than	  drug-­‐maintained	  behavior.	  Caine	  and	  Koob	  (1994)	  tested	  the	  effects	  of	  50,	  100,	  200,	  and	  400	  μg/kg	  raclopride	  on	  operant	  behavior	  in	  a	  multiple	  schedule	  in	  which	  periods	  of	  cocaine	  availability	  alternated	  with	  periods	  of	  food	  availability.	  Raclopride	  reduced	  responding	  for	  food	  to	  a	  greater	  extent	  than	  cocaine	  across	  doses,	  but	  these	  effects	  were	  only	  statistically	  significant	  at	  the	  two	  highest	  doses	  tested.	  Similarly,	  Weissenborn,	  Deroche,	  Koob,	  and	  Weiss	  (1996)	  tested	  the	  effects	  of	  100,	  200,	  and	  400	  µg/kg	  raclopride	  on	  food-­‐	  and	  cocaine-­‐maintained	  behavior	  in	  a	  multiple	  schedule.	  They	  reported	  a	  downward	  trend	  in	  food-­‐maintained	  behavior	  across	  doses,	  but	  these	  differences	  did	  not	  reach	  statistical	  significance.	  So,	  while	  there	  is	  some	  evidence	  of	  raclopride	  having	  differential	  effects	  on	  ongoing	  food-­‐	  and	  drug-­‐maintained	  behavior,	  it	  is	  not	  clear	  whether	  these	  results	  apply	  to	  relapse	  of	  extinguished	  behavior.	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The	  results	  concerning	  the	  effects	  of	  raclopride	  on	  target	  lever	  pressing	  across	  Phase	  III	  sessions	  are	  not	  particularly	  surprising	  considering	  the	  well-­‐documented	  effects	  of	  D2	  antagonists	  on	  various	  types	  of	  relapse.	  However,	  raclopride	  also	  significantly	  impacted	  extinction	  of	  the	  alternative	  nose	  poke	  across	  Phase	  III	  sessions.	  Furthermore,	  raclopride	  almost	  completely	  suppressed	  alternative	  pokes	  at	  both	  doses	  tested.	  To	  my	  knowledge,	  no	  studies	  have	  directly	  investigated	  the	  effects	  of	  dopamine	  D2	  antagonists	  on	  extinction	  of	  operant	  responding.	  However,	  Aberman,	  Ward,	  and	  Salamone	  (1998)	  explored	  the	  effects	  of	  raclopride	  on	  progressive-­‐ratio	  performance,	  in	  which	  a	  response	  requirement	  is	  increased	  after	  each	  reinforcer	  delivery.	  Aberman	  and	  colleagues	  found	  that	  raclopride	  administered	  at	  doses	  comparable	  to	  those	  used	  in	  Experiment	  1	  suppressed	  progressive-­‐ratio	  responding	  resulting	  in	  decreases	  in	  the	  highest	  ratio	  completed.	  If	  extinction	  is	  conceptualized	  as	  an	  infinitely	  long	  response	  requirement,	  then	  such	  results	  in	  progressive	  ratio	  schedules	  may	  have	  some	  bearing	  on	  the	  effects	  of	  D2	  antagonists	  during	  extinction,	  and	  the	  results	  concerning	  the	  alternative	  poke	  are	  not	  that	  surprising.	  	  However,	  the	  results	  of	  Aberman	  et	  al.	  do	  not	  speak	  to	  the	  speed	  at	  which	  raclopride	  eliminated	  the	  alternative	  poke	  in	  the	  present	  study.	  In	  light	  of	  previous	  research	  it	  is	  interesting	  that	  in	  the	  present	  study	  impairments	  of	  motivation	  to	  initiate	  responding	  and	  motivation	  to	  persist	  in	  responding	  were	  aligned	  with	  one	  another.	  Alleweireldt	  and	  colleagues	  (2002)	  tested	  the	  effects	  of	  the	  dopamine	  D1	  antagonist	  SCH	  23390	  on	  cue-­‐induced	  cocaine	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seeking,	  and	  reported	  dissociable	  effects	  of	  deficits	  in	  initiation	  and	  persistence.	  That	  is,	  SCH	  23390	  did	  not	  affect	  motivation	  to	  initiate	  responding,	  but	  decreased	  persistence,	  which	  is	  typical	  of	  responding	  under	  extinction	  conditions.	  These	  differing	  results	  may	  be	  related	  to	  several	  differences	  between	  the	  two	  studies.	  First,	  Alleweireldt	  et	  al.	  examined	  action	  at	  the	  dopamine	  D1	  receptor,	  while	  the	  present	  experiment	  examined	  the	  role	  of	  D2	  receptors.	  There	  is	  evidence	  that	  dopamine	  D2	  receptor	  antagonism	  produces	  greater	  motor	  disruption	  of	  operant	  behavior	  than	  antagonism	  at	  D1	  receptors	  (see	  Fowler	  &	  Liou,	  1998).	  Second,	  target	  responses	  produced	  a	  cue	  that	  accompanied	  cocaine	  deliveries	  in	  the	  past	  in	  the	  Alleweireldt	  et	  al.	  study,	  whereas	  the	  target	  had	  no	  programmed	  consequences	  in	  the	  present	  experiment.	  Finally,	  experimental	  sessions	  lasted	  120	  minutes	  in	  the	  Alleweireldt	  et	  al.	  study,	  whereas	  sessions	  were	  just	  30	  minutes	  long	  in	  the	  present	  experiment.	  Longer	  sessions	  may	  have	  produced	  deficits	  in	  persistence	  within	  the	  50	  µg	  group.	  	   Some	  differences	  emerged	  between	  the	  effects	  of	  raclopride	  on	  the	  target	  versus	  alternative	  response.	  For	  instance,	  patterns	  of	  decline	  across	  Phase	  III	  sessions	  were	  markedly	  different:	  Raclopride	  nearly	  eliminated	  alternative	  pokes	  at	  both	  doses,	  whereas	  some	  target	  lever	  pressing	  occurred	  within	  the	  50	  µg	  group.	  Also,	  in	  measures	  of	  early	  responding	  (i.e.,	  latency	  and	  responses	  in	  first	  2	  minutes),	  raclopride	  had	  clear	  effects	  on	  the	  alternative	  at	  both	  doses	  tested,	  whereas	  only	  the	  100	  µg/kg	  dose	  impacted	  the	  target.	  These	  results	  are	  interesting	  in	  the	  present	  experiment	  in	  that	  both	  responses	  produced	  the	  same	  reinforcer.	  Such	  effects	  may	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be	  attributable	  to	  the	  rates	  at	  which	  the	  responses	  occurred	  prior	  to	  raclopride	  administration.	  That	  is,	  the	  target	  occurred	  at	  a	  much	  lower	  rather	  than	  the	  alternative	  poke.	  However,	  it	  may	  also	  be	  an	  issue	  of	  relapse	  versus	  extinction.	  That	  is,	  reappearance	  of	  an	  extinguished	  response	  versus	  elimination	  of	  a	  previously	  reinforced	  response.	  	   Raclopride	  blocked	  resurgence	  in	  Experiment	  1,	  but	  previous	  studies	  have	  shown	  that	  dopamine	  D2	  antagonists	  are	  ineffective	  in	  blocking	  stress-­‐induced	  reinstatement	  (Capriles	  et	  al.,	  2003;	  Shaham	  &	  Stewart,	  1996;	  Tobin	  et	  al.,	  2009).	  	  This	  provides	  some	  evidence	  that	  the	  food	  or	  drug	  seeking	  observed	  in	  resurgence	  experiments	  is	  not	  stress-­‐induced.	  However,	  one	  of	  the	  primary	  aims	  of	  the	  present	  dissertation	  was	  to	  directly	  examine	  the	  role	  of	  receptors	  known	  to	  impact	  stress-­‐induced	  reinstatement.	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CHAPTER	  IV	  EXPERIMENT	  2:	  THE	  ROLE	  OF	  NORADRENERGIC	  α2	  RECEPTORS	  IN	  RESURGENCE	  
Purpose	  
	   Both	  Podlesnik	  et	  al.	  (2006)	  and	  Quick	  et	  al.	  (2011)	  drew	  parallels	  between	  the	  reinforcer	  loss	  used	  to	  induce	  drug	  seeking	  within	  the	  resurgence	  procedure	  and	  situations	  such	  as	  job	  loss	  or	  divorce,	  which	  can	  produce	  increased	  drug	  taking	  and	  relapse	  within	  human	  populations	  (Falba	  et	  al.,	  2005;	  Gallo	  et	  al.,	  2001;	  San	  Jose	  et	  al.,	  2000;	  Temple	  et	  al.,	  1991).	  These	  and	  similar	  situations	  (e.g.,	  death	  of	  a	  loved	  one,	  loss	  of	  a	  home,	  abandonment,	  etc.)	  are	  typically	  considered	  stressful	  circumstances	  (see	  Sinha,	  2008);	  therefore,	  resurgence	  may	  be	  a	  form	  of	  stress-­‐induced	  relapse.	  	  Experiment	  1	  examined	  the	  role	  of	  dopamine	  D2	  receptors	  in	  resurgence,	  but	  antagonism	  of	  these	  receptors	  fails	  to	  attenuate	  stress-­‐induced	  reinstatement	  (Capriles	  et	  al.,	  2003;	  Shaham	  &	  Stewart,	  1996;	  Tobin	  et	  al.,	  2009).	  The	  purpose	  of	  Experiment	  2	  was	  to	  explore	  the	  role	  of	  receptors	  whose	  blockade	  reduces	  stress-­‐induced	  relapse.	  The	  adrenergic	  α2	  receptor	  was	  chosen	  because	  α2	  agonists	  block	  stress-­‐induced	  reinstatement	  of	  a	  variety	  of	  drugs	  of	  abuse	  (Erb	  et	  al.,	  2000;	  Shaham	  et	  al.,	  2000;	  Lê	  et	  al.,	  2005;	  Zislis	  et	  al.,	  2007).	  	  As	  in	  Experiment	  1,	  rats	  responded	  in	  a	  resurgence	  procedure	  in	  which	  a	  lever	  press	  produced	  food	  deliveries	  during	  Phase	  I,	  the	  lever	  press	  was	  placed	  on	  extinction	  while	  a	  nose	  poke	  produced	  food	  deliveries	  during	  Phase	  II,	  and	  finally	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the	  nose	  poke	  was	  also	  placed	  on	  extinction	  while	  the	  lever	  remained	  on	  extinction	  during	  Phase	  III.	  Separate	  groups	  of	  animals	  were	  injected	  with	  vehicle	  or	  one	  of	  two	  doses	  of	  the	  α2	  receptor	  agonist	  clonidine	  prior	  to	  Phase	  III	  sessions.	  	  	  
Method	  
Subjects	  	   An	  additional	  24	  experimentally	  naïve	  male	  Long-­‐Evans	  rats	  were	  used	  in	  the	  present	  experiment.	  Details	  regarding	  housing,	  deprivation,	  and	  experimental	  handling	  were	  identical	  to	  those	  experienced	  by	  the	  animals	  in	  Experiment	  1.	  
Apparatus	  Four	  additional	  MED-­‐Associates	  chambers	  were	  used	  for	  Experiment	  2.	  These	  chambers	  were	  identical	  to	  those	  used	  in	  the	  previous	  experiment	  with	  the	  exception	  of	  details	  involving	  the	  levers,	  lever	  lights,	  and	  pellet	  receptacle.	  In	  these	  four	  chambers,	  an	  identically	  sized	  aperture	  (5	  cm	  ×	  5	  cm)	  sits	  between	  two	  fixed	  (i.e.,	  non-­‐retractable)	  levers;	  however,	  this	  aperture	  is	  divided	  in	  half	  vertically,	  and	  pellets	  are	  delivered	  on	  the	  right	  side.	  Above	  each	  lever	  to	  the	  left	  and	  right	  of	  the	  food	  aperture	  is	  a	  series	  of	  colored	  LEDs	  (red,	  yellow,	  green).	  
Drug	   The	  α2	  adrenergic	  receptor	  agonist	  clonidine	  was	  used	  in	  the	  present	  study.	  Separate	  groups	  of	  rats	  (n	  =	  8)	  were	  injected	  with	  0	  (vehicle),	  20,	  or	  40	  μg/kg	  of	  the	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drug.	  These	  doses	  were	  chosen	  based	  on	  previous	  studies	  that	  demonstrated	  successful	  attenuation	  of	  shock-­‐induced	  reinstatement	  without	  motor	  impairment	  (Erb	  et	  al.,	  2000;	  Shaham	  et	  al.,	  2000).	  All	  drug	  doses	  were	  prepared	  at	  an	  injection	  volume	  of	  1	  ml/kg.	  Clonidine	  or	  saline	  was	  administered	  via	  intraperitoneal	  injection	  40	  minutes	  prior	  to	  experimental	  sessions.	  	  
Procedure	  
Training.	  Magazine	  training	  occurred	  as	  described	  in	  Experiment	  1	  with	  pellets	  being	  delivered	  according	  to	  a	  VT	  60-­‐s	  schedule	  in	  a	  30-­‐minute	  session.	  The	  two	  additional	  FR	  1	  training	  sessions	  also	  occurred	  as	  described	  in	  Experiment	  1.	  
Phases	  I,	  II,	  and	  III.	  Animals	  in	  Experiment	  2	  experienced	  identical	  experimental	  phases	  as	  outlined	  in	  the	  first	  experiment.	  Briefly,	  rats	  lever	  pressed	  for	  pellets	  according	  to	  a	  VI	  45-­‐s	  schedule	  for	  20	  sessions	  (Phase	  I),	  followed	  by	  extinction	  of	  the	  lever	  press	  in	  conjunction	  with	  reinforcement	  of	  the	  center	  nose	  poke	  according	  to	  a	  VI	  10-­‐s	  schedule	  for	  10	  sessions	  (Phase	  II),	  and	  finally	  both	  responses	  were	  placed	  on	  extinction	  for	  5	  sessions	  (Phase	  III).	  Prior	  to	  Phase	  III	  sessions,	  rats	  were	  injected	  with	  0	  (vehicle),	  20,	  or	  40	  μg/kg	  of	  the	  α2	  receptor	  agonist	  clonidine.	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Results	  
Phase	  I	  Animals	  acquired	  the	  target	  lever	  response	  without	  incident	  as	  in	  Experiment	  1.	  The	  top	  portion	  of	  Table	  4	  shows	  response	  rates	  and	  reinforcer	  rates	  averaged	  over	  the	  last	  3	  sessions	  of	  Phase	  I.	  Again,	  rats	  were	  assigned	  to	  treatment	  groups	  so	  as	  to	  equate	  average	  target	  lever	  rates,	  and	  these	  groups	  were	  highly	  similar	  in	  terms	  of	  those	  rates,	  F(2,21)	  =	  .01,	  p	  =	  .995.	  Inactive	  lever	  rates	  tended	  to	  be	  higher	  than	  either	  the	  alternative	  or	  other	  pokes,	  but	  all	  of	  these	  responses	  occurred	  at	  rates	  much	  lower	  than	  the	  target.	  Food	  rates	  also	  did	  not	  differ	  across	  groups,	  F(2,21)	  =	  .47,	  p	  =	  .633,	  and	  were	  close	  to	  the	  programmed	  rate	  of	  reinforcement	  (i.e.,	  1.33	  foods	  per	  minute).	  	  
Phase	  II	  One	  rat	  belonging	  to	  the	  0	  μg	  group	  (N6)	  experienced	  an	  additional	  Phase	  II	  session	  because	  of	  a	  substantial	  decrease	  in	  response	  rates	  during	  session	  10.	  Response	  rates	  nearly	  recovered	  to	  their	  prior	  levels	  in	  the	  following	  session,	  so	  N6	  proceeded	  to	  Phase	  III	  and	  its	  data	  (with	  the	  exception	  of	  session	  10)	  were	  included	  in	  all	  data	  analyses.	  As	  shown	  in	  the	  bottom	  portion	  of	  Table	  4,	  response	  rates	  on	  the	  target	  lever	  were	  low	  with	  the	  extinction	  contingencies	  in	  effect,	  and	  did	  not	  differ	  across	  groups,	  F(2,21)	  =	  .77,	  p	  =	  .477.	  As	  in	  Experiment	  1,	  rates	  of	  the	  alternative	  nose	  poke	  response	  at	  the	  end	  of	  Phase	  II	  were	  much	  higher	  than	  at	  the	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  end	  of	  Phase	  I,	  and	  although	  rates	  in	  the	  40	  μg	  group	  were	  lower	  than	  the	  other	  two	  groups,	  these	  differences	  did	  not	  reach	  statistical	  significance,	  F(2,21)	  =	  .69,	  p	  =	  .515.	  As	  expected,	  food	  rates	  were	  also	  higher	  than	  in	  Phase	  I,	  and	  were	  similar	  across	  groups,	  F(2,21)	  =	  .10,	  p	  =	  .904.	  As	  in	  Experiment	  1,	  obtained	  rates	  of	  reinforcement	  fell	  short	  of	  the	  programmed	  rates	  (i.e.,	  6	  foods	  per	  minute).	  With	  the	  exception	  of	  the	  40	  μg	  group,	  inactive	  lever	  presses	  decreased	  from	  Phase	  I	  to	  Phase	  
Table	  4	  
	  
Mean	  (SEM)	  Response	  and	  Food	  Rates	  Averaged	  over	  the	  Final	  Three	  
Sessions	  of	  Phase	  I	  and	  Phase	  II	  for	  Rats	  in	  Experiment	  2	  
	  	  
Group0'μg 20'μg 40'μgPhase'ITarget 32.77'(8.26) 33.07'(9.19) 33.93'(7.55)Alt 0.12'(0.03) 0.08'(0.03) 0.12'(0.04)Inactive 0.99'(0.42) 2.75'(1.67) 1.28'(0.44)Other 0.73'(0.20) 0.44'(0.18) 0.57'(0.21)Foods 1.19'(0.03) 1.22'(0.02) 1.19'(0.03)Phase'IITarget 2.74'(0.76) 2.22'(0.29) 3.87'(1.45)Alt 48.54'(11.42) 52.81'(11.98) 36.75'(5.40)Inactive 0.32'(0.15) 0.69'(0.34) 1.91'(1.38)Other 4.98'(1.51) 3.79'(2.38) 7.44'(2.41)Foods 4.62'(0.40) 4.79'(0.21) 4.66'(0.17)
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II;	  however,	  rates	  of	  responding	  in	  the	  other	  nose	  pokes	  increased	  for	  all	  groups	  as	  they	  did	  in	  Experiment	  1.	  
Phase	  III	  
Resurgence	  in	  first	  Phase	  III	  session.	  As	  in	  Experiment	  1,	  responding	  on	  the	  target	  lever	  between	  Phase	  II	  and	  III	  was	  examined	  in	  the	  context	  of	  the	  inactive	  lever	  and	  other	  pokes	  to	  ensure	  that	  increased	  responding	  was	  specific	  to	  a	  response	  that	  previously	  produced	  food	  deliveries.	  Response	  rates	  on	  the	  target	  lever	  in	  the	  last	  session	  of	  Phase	  II	  and	  the	  first	  of	  Phase	  III	  are	  shown	  in	  the	  top	  panel	  of	  Figure	  7.	  As	  in	  Experiment	  1,	  responding	  was	  generally	  higher	  during	  Phase	  III,	  and	  varied	  according	  to	  clonidine	  treatment.	  A	  mixed	  ANOVA	  with	  Dose	  as	  a	  between-­‐subjects	  factor	  and	  Phase	  as	  a	  repeated	  factor	  supported	  this	  account,	  indicating	  a	  significant	  main	  effect	  of	  Phase,	  F(1,21)	  =	  20.39,	  p	  <	  .001,	  and	  significant	  interaction,	  F(2,21)	  =	  5.55,	  p	  =	  .012,	  but	  the	  main	  effect	  of	  Dose	  failed	  to	  reach	  significance,	  F(2,21)	  =	  1.43,	  p	  =	  .261.	  Follow-­‐up	  paired	  t-­‐tests	  comparing	  Phase	  II	  significant	  resurgence	  in	  the	  0	  μg,	  t(7)	  =	  -­‐4.12,	  p	  =	  .004,	  and	  20	  μg,	  t(7)	  =	  -­‐2.43,	  p	  =	  .045,	  but	  not	  40	  μg	  group,	  t(7)	  =	  -­‐.44,	  p	  =	  .672.	  Thus,	  clonidine	  attenuated	  resurgence	  of	  the	  target	  lever	  at	  both	  doses	  tested,	  but	  only	  significantly	  at	  the	  highest	  dose	  tested,	  40	  μg.	  The	  middle	  panel	  of	  Figure	  7	  shows	  response	  rates	  on	  the	  inactive	  lever	  in	  the	  last	  session	  of	  Phase	  II	  and	  the	  first	  of	  Phase	  III.	  Inactive	  lever	  pressing	  was	  lower	  in	  the	  0	  and	  20	  μg	  groups	  than	  in	  the	  40	  μg	  group	  across	  phases.	  The	  0	  and	  20	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μg	  also	  showed	  negligible	  increases	  in	  inactive	  lever	  pressing,	  whereas	  the	  40	  μg	  group	  showed	  a	  slight	  decrease.	  However,	  none	  of	  these	  differences	  were	  significant:	  The	  mixed	  ANOVA	  produced	  nonsignificant	  main	  effects	  of	  Phase,	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F(1,21)	  =	  .001,	  p	  =	  .970,	  and	  Dose,	  F(2,21)	  =	  1.00,	  p	  =	  .383,	  as	  well	  as	  a	  nonsignificant	  interaction,	  F(2,21)	  =	  2.15,	  p	  =	  .142.	  The	  bottom	  panel	  of	  Figure	  7	  shows	  response	  rates	  on	  the	  other	  nose	  pokes.	  Like	  the	  inactive	  lever	  presses,	  these	  pokes	  tended	  to	  occur	  less	  frequently	  in	  the	  0	  and	  20	  μg	  groups	  as	  compared	  to	  the	  40	  μg	  group.	  Both	  groups	  treated	  with	  clonidine	  showed	  decreased	  levels	  of	  other	  poking	  in	  Phase	  III,	  whereas	  other	  pokes	  in	  the	  0	  μg	  group	  were	  roughly	  the	  same.	  Significantly	  fewer	  other	  pokes	  occurred	  in	  Phase	  III	  as	  evidence	  by	  the	  mixed	  ANOVA	  producing	  a	  significant	  effect	  of	  Phase,	  F(1,21)	  =	  6.32,	  p	  =	  .020.	  No	  other	  differences	  were	  significantly	  different,	  as	  indicated	  by	  the	  main	  effect	  of	  Dose,	  
F(2,21)	  =	  .69,	  p	  =	  .514,	  and	  the	  interaction,	  F(2,21)	  =	  1.61,	  p	  =	  .223,	  failing	  to	  reach	  significance.	  	  Resurgence	  specific	  to	  the	  target	  lever	  occurred	  in	  the	  0	  and	  20	  μg	  groups,	  but	  was	  blocked	  by	  40	  μg	  of	  clonidine.	  Although	  responses	  to	  the	  other	  nose	  pokes	  decreased	  in	  Phase	  III	  as	  in	  Experiment	  1,	  it	  is	  more	  difficult	  to	  say	  that	  this	  decrease	  was	  a	  product	  of	  the	  experimental	  contingencies	  and	  not	  the	  drug	  effects,	  because	  no	  such	  decrease	  was	  observed	  in	  the	  0	  μg	  group.	  	  
Across	  Phase	  III	  sessions.	  The	  top	  panel	  of	  Figure	  8	  shows	  target	  lever	  rates	  across	  Phase	  III	  sessions.	  A	  mixed	  ANOVA	  with	  Dose	  as	  a	  between-­‐subjects	  factor	  and	  Session	  as	  a	  repeated	  measure	  showed	  that	  response	  rates	  decreased	  across	  sessions	  as	  indicated	  by	  a	  significant	  main	  effect	  of	  Session,	  F(4,84)	  =	  19.26,	  p	  <	  .001,	  and	  were	  impacted	  by	  clonidine	  as	  indicated	  by	  a	  significant	  main	  effect	  of	  Dose,	  F(2,21)	  =	  4.04,	  p	  =	  .033.	  Fisher’s	  test	  showed	  that	  responding	  was	  significantly	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lower	  in	  the	  40	  μg	  group	  than	  the	  0	  μg	  group,	  but	  no	  other	  comparisons	  reached	  significance.	  Rate	  of	  decline	  was	  similar	  across	  groups	  as	  indicated	  by	  a	  nonsignificant	  interaction,	  F(8,84)	  =	  1.506,	  p	  =	  .167.	  Thus,	  40	  μg	  clonidine	  reduced	  target	  responding	  across	  Phase	  III	  sessions,	  but	  did	  not	  appear	  to	  hasten	  the	  rate	  of	  decline	  across	  those	  sessions.	  	  	  
.	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The	  bottom	  panel	  of	  Figure	  8	  shows	  response	  rates	  on	  the	  alternative	  poke	  across	  Phase	  III	  sessions.	  Although	  responding	  in	  the	  40	  μg	  group	  was	  somewhat	  suppressed	  in	  the	  first	  session,	  rates	  of	  the	  alternative	  poke	  decreased	  similarly	  across	  sessions	  in	  all	  groups.	  A	  mixed	  ANOVA	  supported	  this	  interpretation	  yielding	  a	  significant	  main	  effect	  of	  Session,	  F(4,84)	  =	  51.43,	  p	  <	  .001,	  but	  not	  Dose,	  F(2,21)	  =	  .76,	  p	  =	  .478,	  nor	  interaction,	  F(8,84)	  =	  1.97,	  p	  =	  .060.	  Although	  the	  interaction	  almost	  reached	  statistical	  significance,	  the	  effect	  of	  Dose	  did	  not	  reach	  significance	  within	  any	  of	  the	  Phase	  III	  sessions	  (all	  p	  values	  >	  .20)	  indicating	  that	  clonidine	  did	  not	  significantly	  impact	  extinction	  of	  the	  alternative	  poke	  response	  across	  Phase	  III	  sessions.	  Thus,	  clonidine	  reduced	  activity	  at	  the	  target	  lever	  across	  Phase	  III	  sessions	  while	  leaving	  activity	  at	  the	  alternative	  poke	  relatively	  intact.	  
Motivational	  versus	  motor	  impairment.	  As	  in	  Experiment	  1,	  a	  number	  of	  measures	  were	  analyzed	  to	  determine	  whether	  clonidine	  suppressed	  resurgence	  via	  alteration	  of	  motivation	  or	  by	  impairing	  motor	  performance.	  These	  measures	  examined	  motivation	  to	  initiate	  responding,	  motivation	  to	  respond	  throughout	  the	  session,	  and	  ability	  to	  respond.	  	  	   Motivation	  to	  initiate	  responding.	  The	  top	  panel	  of	  Figure	  9	  shows	  the	  effects	  of	  clonidine	  on	  mean	  (±SEM)	  latencies	  to	  the	  first	  target	  and	  alternative	  responses	  in	  the	  first	  Phase	  III	  session,	  and	  individual	  subject	  data	  are	  displayed	  in	  Table	  5.	  Subjects	  were	  quicker	  to	  initiate	  responding	  on	  the	  alternative	  response,	  but	  clonidine	  had	  no	  systematic	  effects	  on	  the	  target	  or	  alternative.	  This	  was	  supported	  by	  a	  mixed	  ANOVA	  with	  Response	  as	  a	  within-­‐subjects	  factor	  and	  Dose	  as	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a	  between-­‐subjects	  factor	  that	  yielded	  a	  significant	  main	  effect	  of	  Response,	  F(1,21)	  =	  7.74,	  p	  =	  .011,	  but	  neither	  Dose,	  F(1,21)	  =	  .72,	  p	  =	  .499,	  nor	  interaction,	  F(1,21)	  =	  .64,	  p	  =	  .540.	  	  The	  bottom	  panel	  of	  Figure	  9	  shows	  the	  effects	  of	  clonidine	  on	  target	  and	  alternative	  responses	  in	  the	  first	  2	  minutes	  of	  the	  first	  Phase	  III	  session,	  and	  individual	  subject	  data	  for	  these	  measures	  are	  also	  shown	  in	  Table	  5.	  As	  in	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Experiment	  1,	  more	  responding	  occurred	  on	  the	  alternative	  poke	  than	  the	  target	  lever.	  Clonidine	  subtly,	  dose-­‐dependently	  reduced	  initial	  responding	  on	  the	  target	  lever,	  but	  seemed	  to	  have	  much	  more	  pronounced	  effects	  on	  the	  alternative	  poke.	  This	  interpretation	  was	  not	  supported	  statistically	  in	  that	  the	  mixed	  ANOVA	  only	  indicated	  a	  significant	  effect	  of	  Response,	  F(1,21)	  =	  59.18,	  p	  <	  .001,	  but	  not	  Dose,	  
F(1,21)	  =	  1.99,	  p	  =	  .162,	  nor	  interaction,	  F(1,21)	  =	  1.73,	  p	  =	  .202.	  Thus,	  although	  there	  appeared	  to	  be	  some	  effect	  on	  early	  alternative	  responses,	  especially	  on	  the	  number	  of	  alternative	  pokes	  within	  the	  first	  2	  minutes,	  clonidine	  did	  not	  produce	  any	  statistically	  different	  effects.	  	  	   Motivation	  across	  the	  session.	  As	  in	  Experiment	  1,	  persistence	  scores	  for	  the	  target	  and	  alternative	  responses	  were	  calculated	  by	  subtracting	  the	  time	  of	  the	  first	  response	  from	  the	  time	  of	  the	  last	  response.	  The	  effects	  of	  clonidine	  on	  mean	  (±SEM)	  persistence	  scores	  are	  displayed	  in	  Figure	  10.	  Individual	  subject	  data	  are	  shown	  in	  Table	  5.	  Persistence	  of	  the	  alternative	  response	  tended	  to	  be	  greater	  than	  the	  target	  for	  both	  groups	  treated	  with	  clonidine.	  This	  was	  supported	  by	  a	  mixed	  ANOVA	  with	  Response	  as	  a	  within-­‐subjects	  factor	  and	  Dose	  as	  a	  between-­‐subjects	  factor	  that	  yielded	  a	  significant	  effect	  of	  Response,	  F(1,21)	  =	  4.87,	  p	  =	  .039,	  but	  not	  Dose,	  F(1,21)	  =	  1.24,	  p	  =	  .311,	  and	  a	  nearly	  significant	  interaction,	  F(1,21)	  =	  3.42,	  p	  =	  .052.	  The	  marginally	  significant	  interaction	  was	  analyzed	  further.	  First,	  the	  effect	  of	  Dose	  was	  examined	  for	  each	  response,	  but	  did	  not	  reach	  significance	  for	  the	  Target,	  
F(2,21)	  =	  2.42,	  p	  =	  .113,	  nor	  Alternative,	  F(2,21)	  =	  1.04,	  p	  =	  .370.	  Accordingly,	  follow-­‐up	  paired	  t-­‐tests	  comparing	  the	  two	  responses	  were	  conducted	  for	  each	  dose,	  and	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these	  indicated	  that	  the	  responses	  did	  not	  differ	  in	  the	  0	  μg	  group,	  t(7)	  =	  .55,	  p	  =	  
.599,	  but	  did	  in	  the	  20	  μg,	  t(7)	  =	  -­‐3.17,	  p	  =	  .016,	  and	  40	  μg	  group,	  t(7)	  =	  -­‐2.94,	  p	  =	  .022.	  Thus,	  although	  responding	  occurred	  throughout	  most	  of	  the	  session	  across	  the	  groups,	  clonidine	  made	  the	  target	  response	  less	  persistent	  at	  both	  doses	  tested.	  	  Cumulative	  target	  lever	  presses	  within	  the	  last	  Phase	  II	  and	  first	  Phase	  III	  sessions	  were	  also	  compared	  to	  examine	  whether	  response	  patterns	  were	  like	  those	  observed	  under	  extinction	  conditions	  (see	  Quick	  et	  al.,	  2011),	  and	  these	  data	  are	  shown	  in	  Figure	  11.	  A	  Phase	  ×	  Dose	  ×	  Bin	  mixed	  ANOVA	  yielded	  a	  significant	  3-­‐way	  interaction,	  F(28,294)	  =	  4.93,	  p	  <	  .001,	  along	  with	  all	  other	  2-­‐way	  interactions	  and	  main	  effects	  reaching	  significance,	  with	  the	  exception	  of	  Dose,	  F(2,21)	  =	  1.12,	  p	  =	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.345.	  The	  significant	  3-­‐way	  interaction	  was	  first	  followed	  up	  with	  separate	  Dose	  ×	  Bin	  mixed	  ANOVAs	  for	  Phase	  II	  and	  III.	  Responding	  increased	  similarly	  throughout	  the	  last	  Phase	  II	  sessions	  for	  all	  groups	  as	  indicated	  by	  a	  significant	  main	  effect	  of	  Bin,	  F(14,294)	  =	  29.96,	  p	  <	  .001,	  but	  nonsignificant	  main	  effect	  of	  Dose,	  F(2,21)	  =	  .85,	  
p	  =	  .441,	  and	  a	  nonsignificant	  interaction,	  F(28,294)	  =	  .72,	  p	  =	  .848.	  Thus,	  data	  from	  the	  last	  sessions	  of	  Phase	  II	  are	  collapsed	  across	  groups	  in	  Figure	  6	  (open	  diamonds).	  During	  Phase	  III,	  clonidine	  reduced	  cumulative	  target	  presses	  to	  similar	  levels	  below	  that	  of	  the	  0	  µg	  group.	  However,	  analysis	  of	  cumulative	  target	  presses	  during	  Phase	  III	  revealed	  a	  significant	  main	  effect	  of	  Bin,	  F(14,294)	  =	  63.12,	  p	  <	  .001,	  and	  interaction,	  F(28,	  294)	  =	  3.51,	  p	  <	  .001,	  but	  only	  a	  marginally	  significant	  main	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effect	  of	  Dose,	  F(1,21)	  =	  2.85,	  p	  =	  .080.	  	  Unlike	  Experiment	  1,	  output	  on	  the	  target	  lever	  was	  greater	  during	  Phase	  III	  than	  for	  Phase	  II	  in	  each	  of	  the	  group.	  Additional	  Phase	  ×	  Bin	  mixed	  ANOVAs	  were	  conducted	  for	  each	  dose	  to	  compare	  within-­‐session	  response	  patterns	  between	  Phases	  II	  and	  III.	  Patterns	  of	  cumulative	  target	  presses	  were	  significantly	  different	  in	  the	  0	  µg	  [Phase,	  F(1,7)	  	  =	  19.17,	  p	  =	  .003;	  Bin,	  F(14,98)	  =	  24.50,	  p	  <	  .001;	  Interaction,	  
F(14,98)	  =	  14.91,	  p	  <	  .001],	  and	  20	  µg	  groups	  [Phase,	  F(1,7)	  	  =	  5.51,	  p	  =	  .051;	  Bin,	  
F(14,98)	  =	  32.85,	  p	  <	  .001;	  Interaction,	  F(14,98)	  =	  6.40,	  p	  <	  .001],	  but	  not	  in	  the	  40	  
µg	  group	  [Phase,	  F(1,7)	  	  =	  .68,	  p	  =	  .694;	  Bin,	  F(14,98)	  =	  13.18,	  p	  <	  .001;	  Interaction,	  
F(14,98)	  =	  .87,	  p	  =	  .594].	  Thus,	  there	  was	  no	  evidence	  in	  the	  cumulative	  target	  data	  that	  clonidine	  decreased	  behavior	  to	  levels	  lower	  than	  observed	  under	  extinction	  conditions.	  
Ability	  to	  respond.	  Again,	  IRTs	  for	  the	  target	  and	  alternative	  were	  examined	  to	  determine	  whether	  ability	  to	  respond	  was	  impaired.	  The	  top	  panel	  of	  Figure	  12	  shows	  IRTs	  for	  the	  target	  and	  alternative	  responses.	  Table	  5	  shows	  individual	  subject	  mean	  (SD)	  IRTs,	  as	  well	  as	  the	  number	  of	  responses	  on	  which	  those	  averages	  are	  based.	  Responses	  to	  the	  alternative	  tended	  to	  occur	  in	  quick	  succession	  and	  were	  largely	  unaffected	  by	  clonidine.	  IRTs	  for	  the	  target	  response	  were	  longer	  than	  the	  alternative,	  and	  were	  dose-­‐dependently	  increased	  by	  clonidine.	  A	  mixed	  ANOVA	  (Response	  ×	  Dose)	  produced	  a	  significant	  main	  effect	  of	  Response,	  F(1,21)	  =	  28.57,	  p	  <	  .001,	  but	  neither	  Dose,	  F(1,21)	  =	  .41,	  p	  =	  .669,	  nor	  interaction,	  F(1,21)	  =	  1.55,	  p	  =	  .235.	  Therefore,	  although	  there	  was	  some	  visual	  differentiation	  in	  the	  effects	  of	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clonidine	  on	  the	  two	  responses,	  these	  differences	  were	  not	  statistically	  significant.	  Inactive	  and	  other	  nose	  pokes	  were	  also	  examined	  to	  rule	  out	  general	  disruption	  of	  behavior.	  The	  bottom	  panel	  of	  Figure	  12	  shows	  response	  rates	  for	  the	  inactive	  lever	  and	  other	  nose	  pokes	  during	  the	  first	  Phase	  III	  session,	  and	  individual	  subject	  data	  are	  shown	  in	  Table	  5.	  Inactive	  lever	  rates	  tended	  to	  be	  lower	  than	  rates	  of	  other	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pokes,	  however	  clonidine	  did	  not	  appear	  to	  produce	  any	  systematic	  changes	  in	  either	  response.	  This	  interpretation	  was	  supported	  by	  a	  significant	  main	  effect	  of	  Response,	  F(1,21)	  =	  9.15,	  p	  <	  .001,	  but	  neither	  Dose,	  F(1,21)	  =	  1.31,	  p	  =	  .292,	  nor	  interaction,	  F(1,21)	  =	  1.80,	  p	  =	  .190.	  	   As	  in	  Experiment	  1,	  alternative	  nose	  pokes	  occurred	  more	  frequently	  than	  target	  lever	  presses,	  and	  response	  rates	  to	  the	  other	  nose	  pokes	  were	  higher	  than	  to	  the	  inactive	  lever.	  Unlike	  Experiment	  1,	  analyses	  of	  IRTs	  and	  rates	  of	  inactive	  lever	  presses	  and	  other	  nose	  pokes	  indicated	  the	  clonidine	  did	  not	  impact	  ability	  to	  respond	  or	  produce	  any	  general	  disruption	  to	  behavior	  in	  the	  first	  Phase	  III	  session.	  
Discussion	  
	   As	  in	  Experiment	  1,	  the	  groups	  were	  very	  similar	  in	  terms	  of	  response	  and	  reinforcer	  rates	  across	  Phases	  I	  and	  II.	  However,	  different	  patterns	  emerged	  during	  Phase	  III.	  Resurgence	  specific	  to	  the	  target	  lever	  was	  dose-­‐dependently	  reduced	  by	  clonidine,	  but	  to	  levels	  that	  were	  not	  statistically	  different	  from	  Phase	  II	  only	  at	  the	  40	  µg/kg	  dose.	  There	  was	  little	  change	  in	  inactive	  lever	  pressing	  from	  the	  end	  of	  Phase	  II	  to	  the	  beginning	  of	  Phase	  III;	  however,	  clonidine	  reduced	  rates	  of	  other	  pokes	  at	  both	  doses	  tested.	  Clonidine	  also	  dose-­‐dependently	  reduced	  target	  lever	  pressing	  across	  Phase	  III	  sessions,	  but	  did	  not	  impact	  the	  rate	  of	  decline.	  Responses	  to	  the	  alternative	  poke	  showed	  a	  different	  pattern	  across	  Phase	  III	  sessions	  in	  that	  clonidine	  had	  no	  impact	  on	  the	  rate	  of	  extinction.	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Unlike	  Experiment	  1,	  attenuation	  of	  resurgence	  occurred	  largely	  in	  the	  absence	  of	  any	  evidence	  of	  motor	  impairment	  (see	  Table	  6).	  Analyses	  of	  responding	  early	  in	  the	  session	  showed	  that	  rats	  were	  faster	  to	  initiate	  contact	  with	  the	  alternative	  nose	  poke	  than	  the	  target	  lever,	  and	  also	  made	  more	  alternative	  nose	  pokes	  than	  target	  lever	  presses	  in	  the	  first	  2	  minutes	  of	  the	  session.	  However,	  clonidine	  did	  not	  produce	  any	  statistically	  significant	  changes	  in	  either	  of	  these	  measures.	  Analyses	  of	  binned	  cumulative	  target	  presses	  showed	  that	  clonidine	  had	  little	  effect	  on	  within-­‐session	  patterns	  of	  responding,	  and	  more	  (0	  µg)	  or	  equal	  (20	  and	  40	  µg)	  target	  responding	  occurred	  in	  the	  first	  Phase	  III	  session	  as	  compared	  to	  the	  last	  Phase	  II	  session.	  Although	  there	  was	  some	  visual	  evidence	  that	  clonidine	  dose-­‐dependently	  increased	  IRTs	  for	  the	  target,	  the	  statistical	  evidence	  did	  not	  support	  that	  conclusion.	  Similar	  to	  Experiment	  1,	  responding	  was	  less	  frequent	  on	  the	  inactive	  lever	  than	  in	  the	  other	  nose	  pokes;	  however,	  clonidine	  did	  not	  systematically	  affect	  these	  rates.	  	  The	  one	  measure	  in	  which	  clonidine	  produced	  a	  response	  deficit	  was	  persistence	  of	  the	  target	  lever	  press.	  That	  is,	  the	  duration	  of	  the	  session	  during	  which	  target	  lever	  pressing	  occurred	  was	  slightly,	  but	  significantly	  shorter	  than	  it	  was	  for	  the	  alternative	  poke	  in	  both	  of	  the	  groups	  treated	  with	  clonidine.	  Considering	  that	  the	  groups	  did	  not	  vary	  with	  respect	  to	  latency	  to	  initiate	  target	  responding,	  this	  result	  suggests	  that	  these	  animals	  stopped	  responding	  at	  the	  target	  lever	  somewhat	  faster	  than	  they	  did	  the	  alternative.	  As	  noted	  earlier,	  deficits	  in	  persistence	  in	  the	  absence	  of	  any	  deficits	  in	  measures	  of	  motivation	  to	  initiate	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  responding	  are	  indicative	  of	  extinction-­‐like	  behavior	  and	  are	  not	  likely	  attributable	  to	  motor	  impairment	  (see	  Alleweireldt	  et	  al.,	  2002).	  The	  doses	  of	  clonidine	  examined	  in	  Experiment	  2	  were	  chosen	  based	  on	  previous	  studies	  that	  reported	  reduction	  of	  stress-­‐induced	  reinstatement	  in	  the	  absence	  of	  motor	  impairment.	  Erb	  and	  colleagues	  (2000)	  tested	  20	  and	  40	  μg/kg	  clonidine	  and	  found	  that	  while	  these	  doses	  blocked	  stress-­‐induced	  reinstatement	  of	  cocaine	  seeking,	  these	  same	  doses	  did	  not	  impact	  saline	  or	  cocaine-­‐primed	  reinstatement.	  Shaham	  and	  colleagues	  (2000)	  examined	  the	  effects	  of	  0,	  10,	  20,	  and	  40	  µg/kg	  clonidine	  on	  various	  durations	  of	  shock-­‐induced	  reinstatement,	  and	  found	  that	  all	  doses	  tested	  blocked	  reinstatement	  across	  all	  shock	  durations.	  Importantly,	  clonidine	  did	  not	  impact	  active	  or	  inactive	  lever	  pressing	  in	  a	  control	  condition	  
Table	  6	  
Summary	  of	  Statistical	  Comparisons	  Between	  Control	  Group	  (0	  μg)	  and	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when	  rats	  were	  not	  exposed	  to	  shock.	  However,	  at	  least	  one	  study	  has	  reported	  results	  that	  suggest	  motor	  impairment	  at	  the	  doses	  tested	  here.	  Smith	  and	  Aston-­‐Jones	  (2011)	  tested	  administration	  of	  5,	  10,	  and	  20	  μg/kg	  clonidine	  on	  cue-­‐induced	  reinstatement	  of	  cocaine	  seeking,	  and	  reported	  that	  only	  the	  20	  μg	  dose	  effectively	  suppressed	  reinstatement	  to	  levels	  statistically	  indistinguishable	  from	  extinction,	  but	  that	  both	  the	  10	  and	  20	  μg/kg	  doses	  significantly	  suppressed	  inactive	  lever	  presses.	  	  In	  the	  present	  study	  clonidine	  did	  not	  impact	  extinction	  of	  the	  alternative	  response.	  Previous	  studies	  have	  examined	  the	  effects	  of	  α2	  agonists	  on	  extinction	  of	  operant	  behavior,	  but	  outcomes	  seem	  to	  be	  affected	  to	  some	  degree	  by	  whether	  cues	  accompanied	  reinforcer	  delivery	  during	  baseline	  and	  whether	  those	  cues	  were	  present	  during	  extinction.	  For	  instance,	  Highfield	  et	  al.	  (2001)	  reported	  that	  lofexidine	  injections	  have	  no	  effect	  on	  extinction	  of	  speedball	  (i.e.,	  cocaine	  +	  heroin)	  self-­‐administration	  if	  cues	  that	  accompanied	  drug	  deliveries	  were	  present	  during	  extinction,	  but	  reduced	  extinction	  responding	  when	  the	  cues	  were	  withheld.	  Consistent	  with	  these	  results,	  Smith	  and	  Aston-­‐Jones	  (2011)	  demonstrated	  that	  20	  μg/kg	  clonidine	  reduced	  cocaine	  seeking	  during	  the	  first	  extinction	  session	  when	  no	  previously	  cocaine-­‐paired	  cues	  were	  present;	  however,	  this	  dose	  of	  clonidine	  also	  significantly	  reduced	  inactive	  lever	  pressing.	  Contrary	  to	  these	  results,	  Buffalari	  et	  al.	  (2012)	  compared	  extinction	  of	  a	  previously	  cocaine-­‐maintained	  response	  between	  groups	  that	  received	  saline	  or	  guanfacine	  prior	  to	  extinction	  sessions	  in	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which	  drug-­‐paired	  cues	  were	  withheld,	  and	  they	  reported	  no	  differences	  between	  the	  two	  groups.	  	  Within	  the	  present	  experiments	  the	  pellet	  receptacle	  was	  lit	  during	  reinforcer	  deliveries,	  but	  no	  such	  cue	  accompanied	  responses	  made	  under	  extinction	  conditions.	  Therefore,	  the	  results	  of	  Experiment	  2	  seem	  most	  consistent	  with	  the	  findings	  of	  Smith	  and	  Aston-­‐Jones	  (2011)	  and	  Buffalari	  et	  al.	  (2012).	  That	  is,	  rates	  of	  decline	  of	  the	  alternative	  poke	  did	  not	  vary	  among	  the	  groups,	  but	  alternative	  rates	  were	  lower	  in	  40	  µg	  group	  during	  the	  first	  Phase	  III	  session	  (see	  bottom	  panel	  of	  Figure	  8),	  although	  not	  significantly	  lower,	  F(2,21)	  =	  1.70,	  p	  =	  .207.	  In	  summary,	  the	  results	  of	  Experiment	  2	  provide	  evidence	  of	  the	  involvement	  of	  α2	  receptors	  in	  resurgence.	  As	  noted,	  earlier,	  α2	  receptors	  are	  involved	  in	  other	  types	  of	  reinstatement,	  so	  Experiment	  2	  provides	  further	  evidence	  of	  common	  neuropharmacology	  among	  the	  widely	  used	  animal	  models	  of	  relapse.	  Data	  concerning	  effects	  of	  clonidine	  on	  the	  alternative	  response	  are	  especially	  interesting	  in	  light	  of	  the	  results	  of	  Experiment	  1.	  More	  specifically,	  raclopride	  virtually	  eliminated	  the	  alternative	  poke	  early	  on	  in	  Phase	  III	  while	  clonidine	  had	  little	  to	  no	  effect.	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CHAPTER	  V	  GENERAL	  DISCUSSION	  
Summary	  
In	  Experiment	  1,	  treatment	  with	  50	  and	  100	  μg/kg	  of	  the	  D2	  antagonist	  raclopride	  significantly	  reduced	  resurgence	  of	  food	  maintained	  behavior.	  However,	  subsequent	  analyses	  of	  measures	  previously	  used	  to	  dissociate	  motor	  and	  motivational	  impairment	  (see	  Alleweireldt	  et	  al.,	  2002;	  Grimm	  et	  al.,	  2011;	  Quick	  et	  al.,	  2011)	  indicated	  that	  the	  reduction	  at	  the	  higher	  dose	  might	  have	  been	  due	  to	  motor	  impairment.	  Although	  the	  lower	  dose	  of	  raclopride	  showed	  little	  indication	  of	  motor	  impairment	  in	  these	  analyses,	  raclopride	  hastened	  the	  rate	  of	  decline	  for	  both	  the	  target	  and	  alternative	  responses	  across	  Phase	  III	  sessions	  at	  both	  doses	  tested.	  Thus,	  it	  is	  difficult	  to	  say	  whether	  motor	  impair	  also	  played	  a	  role	  in	  attenuation	  at	  the	  50	  µg	  dose.	  Raclopride	  appeared	  to	  have	  a	  larger	  impact	  on	  the	  alternative	  poke,	  nearly	  eliminating	  at	  both	  doses	  of	  raclopride	  tested,	  whereas	  the	  same	  suppressive	  effect	  was	  only	  observed	  on	  the	  target	  repose	  at	  the	  100	  µg/kg	  dose.	  Furthermore,	  there	  was	  evidence	  that	  raclopride	  differentially	  affected	  motivation	  to	  initiate	  responding	  in	  that	  the	  drug	  dose-­‐dependently	  reduced	  motivation	  for	  the	  alternative,	  yet	  only	  seemed	  to	  impact	  the	  target	  at	  the	  100	  µg/kg	  dose.	  In	  Experiment	  2,	  administration	  of	  20	  and	  40	  µg/kg	  of	  α2-­‐adrenergic	  agonist	  reduced	  resurgence;	  however,	  only	  the	  highest	  dose	  tested	  effectively	  reduced	  resurgence	  to	  levels	  no	  different	  than	  extinction.	  Subsequent	  analyses	  indicated	  that	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there	  was	  no	  evidence	  of	  motor	  impairment	  at	  either	  dose	  tested.	  Unlike	  Experiment	  1,	  clonidine	  reduced	  responding	  on	  the	  target	  lever	  across	  Phase	  III	  sessions	  without	  impacting	  the	  rate	  of	  extinction	  of	  the	  alternative	  poke.	  Thus,	  Experiment	  2	  provided	  strong	  evidence	  that	  clonidine	  reduced	  resurgence	  via	  motivational	  rather	  than	  motor	  impairment.	  
Implications	  
Resurgence	  of	  Drug	  Seeking	  The	  present	  studies	  examined	  resurgence	  of	  a	  previously	  food-­‐maintained	  response	  as	  a	  preliminary	  investigation	  into	  whether	  D2	  and	  α2	  receptors	  play	  a	  role	  in	  resurgence.	  However,	  the	  majority	  of	  the	  literature	  that	  has	  informed	  the	  present	  design	  has	  examined	  relapse	  to	  drug	  seeking.	  Although	  few	  studies	  have	  examined	  the	  effects	  of	  these	  drugs	  on	  relapse	  to	  food	  seeking,	  some	  discrepancies	  have	  been	  noted	  between	  the	  effects	  of	  these	  drugs	  on	  drug	  and	  food	  seeking.	  For	  instance,	  administration	  of	  D2	  antagonists	  has	  previously	  potentiated	  (Ball	  et	  al.,	  2011)	  or	  had	  no	  effect	  (Gál	  &	  Gyertyán,	  2006)	  on	  cue-­‐induced	  reinstatement	  of	  food	  seeking,	  whereas	  these	  drugs	  typically	  reduce	  cue-­‐induced	  drug	  seeking	  (Gál	  &	  Gyertyán,	  2006;	  Liu	  et	  al.,	  2010;	  Tobin	  et	  al.,	  2009).	  Also,	  adrenergic	  α2	  agonists	  do	  not	  reduce	  yohimbine-­‐induced	  reinstatement	  of	  food	  seeking	  (Lê	  et	  al.,	  2011;	  Nair	  et	  al.,	  2009),	  whereas	  these	  drugs	  readily	  block	  yohimbine-­‐induced	  drug	  seeking	  (Lê	  et	  al.,	  2009;	  Lee	  et	  al.,	  2003).	  	  Therefore,	  future	  studies	  will	  need	  to	  assess	  the	  effects	  of	  these	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drugs	  on	  resurgence	  of	  drug	  seeking,	  in	  which	  the	  target	  response	  is	  associated	  with	  drug	  deliveries	  and	  the	  alternative	  is	  associated	  with	  a	  nondrug	  reinforcer	  (e.g.,	  Podlesnik	  et	  al.,	  2006;	  Quick	  et	  al.,	  2011).	  The	  fact	  that	  both	  the	  target	  and	  alternative	  response	  produced	  the	  same	  nondrug	  reinforcer	  in	  the	  present	  experiments	  may	  also	  limit	  the	  treatment	  implications	  of	  the	  findings.	  Dissociation	  of	  effects	  on	  drug	  versus	  food	  seeking	  is	  important	  for	  behavioral	  interventions	  that	  attempt	  to	  curb	  drug	  taking.	  However,	  not	  all	  behavioral	  interventions	  aim	  to	  reduce	  drug-­‐maintained	  behavior.	  For	  instance,	  many	  behavioral	  interventions	  attempt	  to	  replace	  maladaptive	  behaviors	  with	  more	  functional	  ones	  that	  result	  in	  the	  same	  consequence.	  
Treatment	  Raclopride	  and	  clonidine	  both	  reduced	  resurgence	  of	  the	  target	  lever	  press,	  but	  raclopride	  also	  suppressed	  the	  alternative	  response,	  while	  clonidine	  had	  minimal	  impact.	  In	  DRA-­‐based	  treatments	  for	  which	  results	  of	  resurgence	  research	  are	  most	  applicable,	  the	  alternative	  response	  is	  typically	  a	  functional	  one	  that	  would	  be	  undesirable	  to	  reduce.	  Based	  on	  the	  present	  results,	  clonidine	  appears	  to	  be	  a	  more	  viable	  option	  as	  a	  pharmacological	  treatment	  to	  supplement	  behavioral	  interventions.	  Interestingly,	  previous	  studies	  have	  examined	  the	  effects	  of	  both	  D2	  antagonists	  and	  α2	  agonists	  on	  drug	  craving	  in	  human	  participants,	  and	  their	  results	  appear	  to	  be	  consistent	  with	  the	  present	  experiments	  with	  respect	  to	  undesirable	  motor	  side	  effects.	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Multiple	  studies	  have	  found	  that	  treatment	  with	  antipsychotic	  medications	  with	  action	  at	  dopamine	  D2	  receptors	  reduce	  cue-­‐elicited	  craving	  in	  abstinent	  cocaine	  (Berger	  et	  al.,	  1996;	  De	  La	  Garza,	  Newton,	  &	  Kalechstein,	  2005;	  Smelson	  et	  al.,	  2004)	  and	  cigarette	  users	  (see	  Matthews,	  Wilson,	  &	  Mitchell,	  2011;	  but	  see	  Mahler	  &	  de	  Wit,	  2005).	  However,	  atypical	  antipsychotic	  drugs	  are	  typically	  favored	  in	  this	  research	  (Hutchison	  et	  al.,	  2004;	  Rohsenow	  et	  al.,	  2008)	  because	  traditional	  antipsychotics	  with	  higher	  affinities	  for	  dopamine	  D2	  receptors	  (e.g.,	  haloperidol)	  tend	  to	  produce	  greater	  motor	  disturbances,	  making	  their	  use	  less	  practical	  (see	  Shirzadi	  &	  Ghaemi,	  2006).	  There	  is	  also	  evidence	  that	  α2	  agonists	  have	  therapeutic	  value	  with	  regard	  to	  craving	  induced	  by	  cues,	  as	  well	  as	  stress.	  Sinha,	  Kimmerling,	  Doebrick,	  and	  Kosten	  (2007)	  reported	  that	  lofexidine	  lowers	  opioid	  cravings	  when	  opioid-­‐dependent	  patients	  are	  read	  scripts	  about	  personal	  stressful	  experiences	  or	  stories	  about	  people,	  places,	  or	  objects	  related	  to	  opioid	  use.	  Sinha	  and	  colleagues	  also	  found	  that	  lofexidine	  increased	  abstinence	  rates	  in	  these	  patients.	  Similarly,	  Jobes	  et	  al.	  (2011)	  found	  that	  clonidine	  lowered	  cocaine	  craving	  in	  response	  to	  hearing	  scripts	  about	  stressful	  events	  and	  drug	  cues.	  However,	  they	  reported	  that	  clonidine	  had	  slightly	  differential	  effects	  on	  stress	  versus	  cues	  in	  that	  both	  doses	  tested	  blocked	  stress-­‐induced	  craving,	  but	  only	  the	  higher	  dose	  blocked	  cue-­‐induced	  craving.	  Thus,	  it	  would	  be	  interesting	  to	  examine	  the	  effects	  of	  α2	  agonists,	  as	  well	  as	  D2	  antagonists,	  during	  situations	  where	  alternative	  reinforcement	  is	  reduced	  and	  problem	  behaviors	  tend	  to	  increase	  (e.g.,	  Volkert	  et	  al.,	  2009).	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Accounts	  of	  Resurgence	  Two	  accounts	  of	  resurgence	  have	  recently	  been	  proposed,	  and	  the	  results	  of	  the	  present	  study	  may	  provide	  some	  indication	  of	  which	  is	  more	  viable.	  The	  first	  is	  that	  resurgence	  is	  a	  form	  of	  contextual	  renewal	  (Bouton	  &	  Swartzentruber,	  1991;	  Winterbauer	  &	  Bouton,	  2010).	  The	  basis	  of	  this	  account	  is	  that	  all	  resurgence	  preparations	  include	  distinct	  changes	  in	  the	  background	  context	  during	  extinction	  and	  testing	  phases	  via	  the	  addition	  of	  alternative	  response	  and	  sources	  of	  reinforcement.	  Although	  context	  in	  renewal	  preparations	  is	  generally	  established	  through	  manipulations	  in	  olfactory,	  auditory,	  visual,	  and	  tactile	  stimuli	  (see	  Crombag	  et	  al.,	  2008),	  Winterbauer	  and	  Bouton	  suggest	  that	  context	  may	  be	  established	  by	  actions,	  as	  well	  as	  their	  consequences.	  This	  account	  suggests	  that	  resurgence	  is	  largely	  cue	  or	  context	  driven.	  Podlesnik	  and	  colleagues	  (2006)	  and	  Quick	  et	  al.	  (2011)	  have	  offered	  an	  alternative	  account	  based	  on	  parallels	  drawn	  between	  the	  reinforcer	  loss	  used	  to	  induce	  drug	  seeking	  within	  the	  procedure	  and	  situations	  such	  as	  job	  loss	  or	  divorce	  that	  tend	  to	  produce	  relapse	  in	  human	  drug	  users	  (Falba	  et	  al.,	  2005;	  Gallo	  et	  al.,	  2001;	  San	  Jose	  et	  al.,	  2000;	  Temple	  et	  al.,	  1991).	  These,	  and	  similar	  situations,	  are	  typically	  considered	  stressful	  (see	  Sinha,	  2008);	  therefore,	  resurgence	  could	  be	  an	  instance	  of	  stress-­‐induced	  relapse	  to	  drug	  seeking.	  	  	   Given	  the	  results	  of	  the	  present	  studies,	  the	  context-­‐driven	  account	  seems	  most	  viable.	  Both	  raclopride	  and	  clonidine	  effectively	  suppressed	  resurgence;	  however,	  raclopride	  has	  repeatedly	  failed	  to	  affect	  stress-­‐induced	  drug	  seeking	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(Capriles	  et	  al.,	  2003;	  Shaham	  &	  Stewart,	  1996;	  Tobin	  et	  al.,	  2009),	  whereas	  there	  is	  some	  evidence	  that	  clonidine	  plays	  a	  role	  in	  cue-­‐induced	  drug	  seeking	  (Smith	  &	  Aston-­‐Jones,	  2011).	  However,	  these	  accounts	  of	  resurgence	  are	  not	  necessarily	  mutually	  exclusive.	  	  There	  is	  evidence	  in	  the	  basic	  literature	  that	  common	  neural	  mechanisms	  mediate	  stress-­‐	  and	  cue-­‐induced	  reinstatement.	  Smith	  and	  Aston-­‐Jones	  (2011)	  found	  that	  administration	  of	  an	  α2	  agonist	  was	  effective	  in	  attenuating	  reinstatement	  via	  cues	  and	  stress,	  but	  also	  that	  administration	  of	  a	  CRF1	  antagonist	  had	  the	  same	  effects.	  Much	  like	  the	  α2	  receptor,	  the	  CRF1	  receptor	  is	  generally	  implicated	  in	  stress-­‐induced	  relapse	  to	  drug	  seeking	  (see	  Shalev,	  Erb,	  &	  Shaham,	  2010),	  but	  also	  appears	  to	  be	  involved	  in	  reinstatement	  via	  drug	  cues	  (Goeders	  &	  Clampitt,	  2002).	  As	  noted	  earlier,	  similar	  findings	  have	  been	  reported	  in	  human	  studies	  (Jobes	  et	  al.,	  2011;	  Sinha	  et	  al.,	  2007).	  Stress	  and	  drugs	  cues	  have	  also	  been	  shown	  to	  produce	  comparable	  levels	  of	  drug	  craving,	  as	  well	  as	  comparable	  physiological	  responses	  in	  human	  drug	  users	  (Sinha,	  Fuse,	  Aubin,	  &	  O’Malley,	  2000).	  Furthermore,	  results	  of	  imaging	  studies	  in	  humans	  indicate	  that	  overlapping	  areas	  of	  the	  brain	  are	  activated	  during	  stress	  and	  cue	  exposure	  (see	  Sinha	  &	  Li,	  2007).	  While	  not	  necessarily	  evidence	  of	  overlap,	  some	  animal	  studies	  have	  shown	  that	  reinstatement	  via	  cues	  and	  stressors	  together	  is	  greater	  than	  either	  alone	  (Buffalari	  &	  See,	  2009,	  2011;	  Feltenstein	  &	  See,	  2006;	  Liu	  &	  Weiss,	  2002a).	  Thus,	  there	  is	  evidence	  that	  these	  systems	  may	  overlap	  or	  interact	  with	  one	  another.	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Limitations	  and	  Future	  Directions	  
Response	  Types	  Within	  the	  present	  experiments	  the	  target	  response	  was	  always	  a	  lever	  press	  and	  the	  alternative	  response	  was	  always	  a	  nose	  poke	  response.	  A	  potential	  criticism	  of	  the	  present	  study	  is	  that	  response	  type	  was	  confounded	  with	  whether	  the	  response	  was	  the	  target	  or	  alternative.	  There	  is	  some	  evidence	  that	  these	  response	  may	  be	  differentially	  impacted	  by	  pharmacological	  manipulation;	  however,	  not	  necessarily	  by	  the	  drugs	  examined	  in	  the	  present	  experiments.	  	  Gerhardt	  and	  Liebman	  (1981)	  tested	  the	  effects	  of	  various	  drugs	  on	  lever	  pressing	  and	  nose	  poking	  maintained	  by	  contingent	  brain	  stimulation.	  Among	  the	  drugs	  examined	  were	  clonidine	  (α2	  agonist)	  and	  haloperidol	  (D2-­‐like	  antagonist).	  Although	  Gerhardt	  and	  Liebman	  reported	  that	  the	  nose	  poke	  response	  was	  less	  susceptible	  to	  disruption	  than	  the	  lever	  press	  under	  some	  of	  the	  drugs	  tested,	  neither	  clonidine	  nor	  haloperidol	  produced	  differential	  disruption.	  While	  these	  results	  suggest	  that	  confounding	  response	  type	  with	  assignment	  to	  target	  versus	  alternative	  may	  not	  be	  of	  concern,	  it	  is	  worth	  noting	  that	  Gerhardt	  and	  Liebman	  examined	  the	  effects	  of	  these	  drugs	  on	  continuous	  reinforcement	  (i.e.,	  fixed	  ratio	  1)	  of	  ongoing	  behavior	  rather	  than	  relapse	  to	  drug	  seeking	  or	  extinction	  of	  responding	  with	  a	  history	  of	  intermittent	  reinforcement.	  Future	  studies	  might	  counterbalance	  response	  type	  across	  the	  target	  and	  alternative	  responses,	  or	  use	  two	  responses	  that	  are	  not	  as	  readily	  emitted	  by	  rats	  (e.g.,	  lever	  press	  and	  chain	  pull).	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Measures	  of	  Motor	  Impairment	  The	  present	  experiments	  examined	  a	  number	  of	  measures	  that	  have	  been	  used	  previously	  to	  dissociate	  the	  effects	  of	  motor	  and	  motivational	  impairment	  (Alleweireldt	  et	  al.,	  2002;	  Grimm	  et	  al.,	  2011;	  Quick	  et	  al.,	  2011).	  	  Although	  the	  results	  of	  these	  analyses	  were	  relatively	  unambiguous	  in	  Experiment	  2,	  the	  results	  of	  Experiment	  1	  are	  more	  difficult	  to	  interpret.	  These	  measures	  gave	  little	  indication	  of	  motor	  impairment	  in	  50	  µg/kg	  raclopride	  group	  within	  the	  first	  Phase	  III	  session,	  but	  responding	  was	  significantly	  suppressed	  across	  Phase	  III	  sessions,	  especially	  with	  respect	  to	  the	  alternative	  poke.	  These	  results	  further	  highlight	  the	  difficulties	  of	  dissociating	  motivational	  and	  motor	  effects	  as	  described	  by	  Grimm	  et	  al.	  (2011).	  However,	  other	  additional	  measures	  have	  also	  been	  used	  to	  dissociate	  motivational	  and	  motor	  drug	  effects,	  and	  no	  single	  study	  has	  used	  all	  of	  them	  together	  (see	  Grimm	  et	  al.,	  2011).	  Future	  studies	  could	  collect	  data	  on	  all	  of	  these	  measures	  to	  confirm	  that	  they	  converge.	  One	  such	  strategy	  is	  comparison	  of	  locomotor	  activity	  during	  drug-­‐free	  sessions	  with	  activity	  during	  sessions	  in	  which	  the	  drug	  is	  administered	  (e.g.,	  Grimm,	  Manaois,	  Osincup,	  Wells,	  &	  Buse,	  2007).	  Locomotor	  activity	  is	  generally	  assessed	  with	  operant	  chambers	  equipped	  with	  multiple	  infrared	  emitters	  and	  detectors	  that	  arrange	  photo-­‐beams	  across	  the	  operant	  chamber.	  Breaks	  in	  the	  photo-­‐beams	  are	  then	  recorded	  and	  compared	  across	  sessions.	  A	  second	  strategy	  is	  to	  determine	  the	  effects	  of	  drugs	  on	  high-­‐rate	  behavior	  maintained	  by	  food	  reinforcers	  (e.g.,	  Erb	  et	  al.,	  2000).	  Drugs	  that	  do	  not	  impact	  performance	  of	  such	  behavior	  presumably	  leave	  motor	  performance	  intact.	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Such	  tests	  are	  also	  important	  for	  dissociating	  selective	  impairment	  of	  drug	  seeking	  in	  other	  models	  of	  drug	  seeking	  that	  do	  not	  involve	  alternative	  nondrug	  reinforcement.	  
Additional	  Receptors	  The	  present	  studies	  examined	  just	  two	  receptors	  that	  have	  proven	  to	  be	  critically	  involved	  in	  various	  other	  models	  of	  relapse	  to	  drug	  seeking,	  but	  a	  number	  of	  other	  receptors	  and	  neural	  systems	  should	  also	  be	  explored.	  In	  addition	  to	  dopamine	  D1	  and	  D2	  receptors,	  D3	  receptors	  have	  also	  been	  implicated	  in	  various	  models	  of	  relapse.	  Several	  studies	  have	  demonstrated	  that	  D3	  antagonists	  block	  drug-­‐primed	  reinstatement	  (Andreoli	  et	  al.,	  2003;	  Higley	  et	  al.,	  2011;	  Khroyan	  et	  al.,	  2000;	  Peng	  et	  al.,	  2009;	  Vorel	  et	  al.,	  2002;	  Xi	  et	  al.,	  2006),	  as	  well	  as	  cue-­‐induced	  reinstatement	  (Cervo,	  Cocco,	  Petrella,	  &	  Heidbreder,	  2007;	  Gilbert	  et	  al.,	  2005;	  Khaled	  et	  al.,	  2010;	  Vengeliene	  et	  al.,	  2006;	  Weiss	  et	  al.,	  2001).	  Results	  are	  mixed	  with	  stress-­‐induced	  reinstatement	  in	  that	  Xi	  et	  al.	  (2006)	  reported	  a	  systemic	  administration	  of	  a	  D3	  antagonist	  blocks	  shock-­‐induced	  reinstatement	  of	  cocaine	  seeking,	  whereas	  Tobin	  et	  al.	  (2009)	  found	  no	  effect	  on	  food	  deprivation-­‐induced	  reinstatement.	  Xi	  and	  colleagues	  also	  tested	  localized	  injections	  and	  found	  that	  administration	  in	  the	  nucleus	  accumbens	  was	  effective	  in	  blocking	  shock-­‐induced	  cocaine	  seeking,	  whereas	  the	  dorsal	  striatum	  was	  not.	  Examination	  of	  D3	  antagonists	  on	  food	  seeking	  is	  limited,	  but	  Cervo	  et	  al.	  (2007)	  reported	  no	  effect	  on	  cue-­‐induced	  reinstatement	  of	  sucrose	  seeking.	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In	  additional	  to	  α2	  adrenergic	  receptors,	  previous	  studies	  have	  also	  examined	  various	  other	  adrenergic	  receptors,	  and	  these	  receptors	  are	  also	  involved	  in	  various	  types	  of	  relapse.	  For	  instance,	  administration	  of	  an	  α1	  antagonist	  blocks	  drug-­‐	  and	  cue-­‐induced	  (Forget	  et	  al.,	  2010;	  Zhang	  &	  Kosten,	  2005),	  but	  not	  stress-­‐induced	  reinstatement	  (Mantsch	  et	  al.,	  2010).	  Leri,	  Flores,	  Rodaros,	  and	  Stewart	  (2002)	  found	  that	  localized	  injections	  of	  a	  mixture	  of	  β1	  and	  β2	  antagonists	  blocks	  stress-­‐induced,	  but	  not	  cocaine	  induced	  reinstatement.	  Mantsch	  and	  colleagues	  (2010)	  found	  parallel	  results	  in	  a	  study	  of	  reinstatement	  of	  conditioned	  place	  preference	  (CPP);	  however,	  the	  results	  of	  Mantsch	  et	  al.	  indicated	  that	  blockade	  of	  β2,	  but	  not	  β1	  receptors	  reduces	  stress-­‐induced	  reinstatement	  of	  CPP.	  	  A	  second	  receptor	  type	  that	  has	  received	  considerable	  attention	  with	  respect	  to	  its	  role	  in	  stress-­‐induced	  drug	  seeking	  is	  the	  CRF1	  receptor	  (see	  Shalev	  et	  al.,	  2010).	  Systemic	  administration	  of	  CRF1	  antagonists	  attenuates	  shock-­‐induced	  reinstatement	  of	  behavior	  previously	  maintained	  by	  a	  variety	  of	  drugs	  (Lê	  et	  al.,	  2000;	  Marinelli	  et	  al.,	  2007;	  Shaham,	  Erb,	  Leung,	  Buczek,	  &	  Stewart,	  1998),	  and	  also	  food	  (Ghitza	  et	  al.,	  2006;	  see	  Nair	  et	  al.,	  2009).	  Although	  CRF	  is	  primarily	  implicated	  in	  stress-­‐induced	  reinstatement,	  some	  studies	  have	  produced	  mixed	  results	  regarding	  its	  role	  in	  priming	  reinstatement,	  blocking	  it	  in	  some	  cases	  (Moffet	  &	  Goeders,	  2007;	  Przegalinski,	  Filip,	  Frankowska,	  Zaniewska,	  &	  Papla,	  2005),	  while	  having	  no	  effect	  in	  others	  (Erb,	  Shaham,	  &	  Stewart,	  1998;	  Lee	  et	  al.,	  2003).	  Antagonism	  of	  CRF	  receptors	  also	  appears	  to	  have	  some	  effect	  on	  cue-­‐induced	  reinstatement,	  but	  again,	  with	  mixed	  results:	  Systemic	  administration	  of	  CP-­‐154,526	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blocks	  cue-­‐induced	  cocaine	  seeking	  (Goeders	  &	  Clampitt,	  2002),	  but	  has	  no	  effect	  on	  cue-­‐induced	  methamphetamine	  seeking	  (Moffett	  &	  Goeders,	  2007).	  The	  endogenous	  cannabinoid	  system	  may	  also	  be	  a	  potential	  target	  for	  future	  studies	  in	  that	  it	  plays	  important	  role	  in	  some	  types	  of	  relapse	  to	  drug	  seeking	  (see	  Fattore	  et	  al.,	  2007).	  For	  instance,	  blockade	  of	  these	  CB1	  receptors	  attenuates	  drug-­‐primed	  reinstatement	  (De	  Vries	  et	  al.,	  2001;	  De	  Vries,	  Homberg,	  Binnekade,	  Raasø,	  &	  Schoffelmeer,	  2003).	  Similar	  to	  the	  dopamine	  D2	  receptor,	  multiple	  studies	  have	  reported	  that	  administration	  of	  CB1	  antagonists	  decreases	  cue-­‐induced	  reinstatement	  while	  having	  no	  effect	  on	  stress-­‐induced	  reinstatement	  (De	  Vries	  et	  al.,	  2001;	  Economidou	  et	  al.,	  2006;	  but	  see	  Vaughn	  et	  al.,	  2012).	  CB1	  receptors	  also	  appear	  to	  play	  a	  role	  in	  contextual	  renewal	  of	  drug	  seeking	  (Diergaarde,	  De	  Vries,	  Raasø,	  Schoffelmeer,	  &	  De	  Vries,	  2008).	  Furthermore,	  CB1	  antagonists	  block	  food-­‐primed	  reinstatement	  (Duarte	  et	  al.,	  2004)	  and	  cue-­‐induced	  reinstatement	  of	  food	  seeking	  (Ward,	  Walker,	  &	  Dystra,	  2007).	  Clonidine	  also	  binds	  with	  high	  affinity	  to	  imidazoline	  receptors	  (Ernsberger,	  Damon,	  Graff,	  Schäfer,	  &	  Christen,	  1993).	  Although	  previous	  studies	  have	  suggested	  that	  it	  is	  unlikely	  that	  clonidine’s	  action	  at	  I1	  receptors	  is	  responsible	  for	  its	  ability	  to	  reduce	  drug	  seeking	  (see	  Shalev	  et	  al.,	  2002),	  Smith	  and	  Aston-­‐Jones	  (2011)	  recently	  reported	  that	  monoxidine,	  an	  I1	  agonist,	  is	  effective	  in	  reducing	  cue-­‐	  and	  cocaine-­‐induced	  reinstatement.	  Therefore,	  future	  studies	  could	  examine	  the	  role	  of	  I1	  receptors.	  It	  would	  also	  be	  of	  interest	  whether	  more	  selective	  α2	  agonists,	  such	  as	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UK-­‐14,304	  or	  guanfacine	  (see	  Smith	  &	  Aston-­‐Jones,	  2011),	  also	  reduce	  resurgence	  to	  provide	  further	  support	  of	  the	  involvement	  of	  α2	  receptors.	  
Targeted	  Approaches	  The	  present	  experiments	  examined	  systemic	  administration	  of	  raclopride	  and	  clonidine	  to	  examine	  the	  role	  of	  D2	  and	  α2	  receptors	  in	  resurgence,	  respectively.	  While	  the	  results	  of	  Experiments	  1	  and	  2	  provide	  preliminary	  evidence	  of	  involvement	  of	  these	  receptors,	  future	  studies	  should	  utilize	  more	  targeted	  approaches	  to	  clarify	  the	  role	  of	  these	  receptors,	  as	  well	  as	  gather	  additional	  information	  about	  the	  role	  of	  specific	  pathways	  in	  the	  brain.	  One	  of	  these	  more	  targeted	  methods	  is	  to	  examine	  the	  role	  of	  specific	  receptors	  using	  genetically	  modified	  animals	  that	  lack	  the	  receptors	  of	  interest	  (Spanagel	  &	  Sanchis-­‐Segura,	  2003).	  Animals	  lacking	  D2	  and	  α2	  receptors	  have	  been	  used	  in	  the	  past	  to	  study	  various	  aspects	  of	  drug	  taking	  and	  drug	  seeking	  (e.g.,	  Caine	  et	  al.,	  2002;	  Wee,	  Mandyam,	  Lekic,	  &	  Koob,	  2008);	  however,	  these	  animals	  also	  display	  behavioral	  deficits	  that	  may	  complicate	  interpretation	  of	  the	  results	  of	  such	  studies	  (Fowler,	  Zarcone,	  Vorontsova,	  &	  Chen,	  2002;	  Spreng,	  Cotecchia,	  &	  Schenk,	  2001).	  A	  second	  approach	  that	  aids	  in	  examination	  of	  specific	  pathways	  is	  to	  test	  the	  effects	  of	  brain	  lesions	  on	  behavior	  in	  animal	  models	  of	  relapse	  (e.g.,	  Yun	  &	  Fields,	  2003).	  	  A	  number	  of	  previous	  studies	  have	  also	  used	  localized	  injections	  of	  different	  agonist	  and	  antagonist	  drugs	  into	  specific	  brain	  regions.	  Relevant	  to	  the	  present	  experiments,	  researchers	  have	  examined	  the	  effects	  of	  targeted	  administration	  of	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dopamine	  D2	  antagonists	  and	  adrenergic	  α2	  agonists	  on	  various	  types	  of	  reinstatement.	  With	  respect	  to	  the	  stress-­‐	  and	  context-­‐based	  accounts	  of	  resurgence	  noted	  earlier,	  it	  would	  be	  most	  informative	  for	  future	  studies	  to	  examine	  a	  location	  in	  the	  brain	  that	  has	  produced	  differential	  attenuation	  of	  cue-­‐	  or	  context-­‐induced	  versus	  stress-­‐induced	  reinstatement.	  That	  is,	  an	  area	  where	  α2	  agonists	  or	  D2	  antagonists	  attenuated	  one	  type	  of	  reinstatement,	  but	  not	  the	  other.	  Unfortunately,	  no	  previous	  studies	  have	  examined	  cue-­‐	  and	  stress-­‐induced	  drug	  seeking	  in	  a	  single	  area	  of	  the	  brain.	  However,	  this	  is	  not	  particularly	  surprising	  considering	  the	  overlap	  and	  interactions	  between	  these	  systems	  noted	  earlier	  (e.g.,	  Liu	  &	  Weiss,	  2002a;	  Sinha	  et	  al.,	  2000).	  Regardless,	  areas	  that	  are	  important	  in	  other	  models	  of	  relapse	  should	  still	  be	  examined.	  	  
Dopamine	  D2	  receptor	  antagonists.	  Dopamine	  D2	  antagonists	  injected	  into	  the	  nucleus	  accumbens	  shell	  appear	  to	  block	  priming	  reinstatement	  of	  drug-­‐maintained	  behavior	  (Anderson,	  Schmidt,	  &	  Pierce,	  2006;	  Bachtell,	  Whisler,	  Karanian,	  &	  Self,	  2005),	  whereas	  administration	  in	  the	  nucleus	  accumbens	  core	  and	  lateral	  septum	  (Anderson	  et	  al.,	  2006),	  as	  well	  as	  the	  prelimbic	  prefrontal	  cortex	  (Capriles	  et	  al.,	  2003)	  does	  not.	  Administration	  in	  the	  dorsal	  prefrontal	  cortex	  attenuates	  reinstatement	  when	  priming	  injections	  of	  cocaine	  are	  combined	  with	  cocaine-­‐paired	  cues	  (Sun	  &	  Rebec,	  2005).	  However,	  injections	  of	  raclopride	  in	  the	  basolateral	  amygdala	  have	  proven	  ineffective	  in	  blocking	  cue-­‐induced	  reinstatement	  of	  drug	  seeking	  (See,	  Kruzich,	  &	  Grimm,	  2001).	  As	  noted	  previously,	  raclopride	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delivered	  to	  the	  prelimbic	  cortex	  or	  orbitofrontal	  cortex	  does	  not	  block	  stress-­‐induced	  reinstatement	  (Capriles	  et	  al.,	  2003).	  Some	  studies	  have	  examined	  the	  effects	  of	  localized	  injections	  of	  D2	  antagonists	  on	  reinstatement	  of	  food	  seeking.	  The	  dorsal	  prefrontal	  cortex	  has	  been	  implicated	  in	  food-­‐primed	  reinstatement	  (Sun	  &	  Rebec,	  2005).	  The	  nucleus	  accumbens	  has	  been	  implicated	  in	  cue-­‐induced	  sucrose	  seeking	  (Guy,	  Choi,	  &	  Pratt,	  2011),	  but	  not	  food-­‐primed	  reinstatement	  in	  a	  runway	  procedure	  (Chausmer	  &	  Ettenberg,	  1999).	  
Adrenergic	  α2	  receptor	  agonists.	  Shaham	  et	  al.	  (2000)	  examined	  how	  inactivation	  of	  two	  primary	  clusters	  of	  adrenergic	  cells	  impacted	  stress-­‐induced	  heroin	  seeking	  and	  reported	  that	  α2	  agonists	  injected	  into	  the	  locus	  coeruleus	  did	  not	  impact	  stress-­‐induced	  reinstatement,	  but	  that	  selective	  6-­‐hydroxydopamine	  lesions	  to	  noradrenergic	  neurons	  in	  the	  lateral	  tegmental	  area	  reduced	  reinstatement	  without	  affecting	  extinction.	  Administration	  of	  α2	  agonists	  in	  the	  central	  nucleus	  of	  the	  amygdala	  also	  appears	  to	  block	  shock-­‐induced	  reinstatement	  (Yamada	  &	  Bruijnzeel,	  2011).	  
Conclusion	  
In	  conclusion,	  the	  present	  experiments	  shed	  additional	  light	  on	  the	  neuropharmacology	  of	  resurgence,	  implicating	  dopamine	  D2	  and	  adrenergic	  α2	  receptors.	  These	  results	  also	  provide	  evidence	  of	  further	  overlap	  among	  the	  popular	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models	  of	  relapse,	  and	  may	  have	  implications	  in	  applied	  settings	  that	  employ	  DRA-­‐based	  treatments	  or	  for	  human	  drug	  users	  in	  which	  stressful	  situations	  characterized	  by	  significant	  loss	  exacerbate	  drug	  use	  or	  induce	  relapse	  to	  maladaptive	  behaviors.	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